

(19)



Europäisches Patentamt

European Patent Office

Office européen des brevets



(11)

**EP 1 160 254 A1**

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:

**05.12.2001 Bulletin 2001/49**

(51) Int Cl.<sup>7</sup>: **C07K 14/435**, C07K 14/705,

C07K 16/28, C12N 15/11,

C12Q 1/68, C12N 15/66,

A61K 38/17, A61P 23/00

(21) Application number: **01304663.6**

(22) Date of filing: **25.05.2001**

(84) Designated Contracting States:

**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE TR**

Designated Extension States:

**AL LT LV MK RO SI**

(30) Priority: **31.05.2000 US 208156 P**

(71) Applicant: **PFIZER INC.**

**New York, N.Y. 10017 (US)**

(72) Inventors:

- **Shinjo, Katsuhiro,**  
**Pfizer Global Res. and Develop.**  
**Chita-gun, Aichi-ken 470-2393 (JP)**

• **Yabuuchi, Hikaru**

**Sagamihara-shi, Kanagawa 228-0811 (JP)**

(74) Representative: **Hayles, James Richard et al**

**Pfizer Limited,**

**Patents Department,**

**Ramsgate Road**

**Sandwich Kent CT13 9NJ (GB)**

### Remarks:

The sequence listing, which is published as annex to the application documents, was filed after the date of filing. The applicant has declared that it does not include matter which goes beyond the content of the application as filed.

(54) **Human vanilloid receptor-like proteins**

(57) This invention relates to human vanilloid receptor-like protein 2 (VRL-2) polypeptides, polynucleotides encoding such polypeptides, polynucleotide probes or primers, expression vectors and host cells comprising such DNA molecules. This invention further relates to a process for producing the polypeptides; an antibody immunospecific for the polypeptide; a diagnostic kit for diagnosing the VRL-2 receptor related disease; a method for screening to identify modulators which modulate the polypeptides; modulators identified by the screening method; a pharmaceutical composition for treatment of conditions associated with biological function of the

polypeptides; and a non-human transgenic animal model for vanilloid receptor-like gene. The polypeptides and the DNA molecules of the present invention can be used to identify agonists, antagonists or the like. These agonists and antagonists are useful for treatment of diseases such as pain, nociceptive pain, chronic pain, neuropathic pain, postoperative pain, cancer pain, rheumatoid arthritic pain, osteoarthritis, diabetic neuropathies, neuralgia, neuropathies, algesia, nerve injury, musculoskeletal pain, low back pain, neurodegeneration, stroke, inflammatory disorders, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension, perivascular disease and the like.

**EP 1 160 254 A1**

**Description****Technical Field**

5 **[0001]** This invention relates to human vanilloid receptor-like protein 2 (VRL-2) polypeptides, polynucleotides encoding such polypeptides, polynucleotide probes or primers, expression vectors and host cells comprising such DNA molecules. This invention further relates to a process for producing the polypeptides; an antibody immunospecific for the polypeptide; a diagnostic kit for diagnosing the VRL-2 receptor related disease; a method for screening to identify  
10 modulators which modulate the polypeptides; modulators obtainable by the screening method; a pharmaceutical composition for treatment of conditions associated with biological function of the polypeptides; and a non-human transgenic animal model for vanilloid receptor-like gene.

**Background Art**

15 **[0002]** The analgesic properties of capsaicin and capsaicinoids are known for their uses in the treatment of a variety of disorders such as pain, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algesia, nerve injury, ischaemia, neurodegeneration stroke incontinence and inflammatory disorders (e. g., Campbell et al. "Clinical Applications of Capsaicin and Its Analogues" in Capsaicin in the Study of Pain, Academic Press pgs. 255-272 (1993)). Capsaicin receptors are believed to be members of the ion channel family of polypeptides.  
20 These receptors are believed to be associated with the mechanism of action of capsaicin (a vanilloid compound). Capsaicin elicits a sensation of burning pain by selectively activating sensory neurons that convey information about noxious stimuli to the central nervous system (e.g., Caterina, M. J. et al., "The Capsaicin Receptor: A Heat Activated Ion Channel In the Pain Pathway", Nature 389, 816-824 (1997) and Caterina, M. J. et al., "A Capsaicin-Receptor Homologue with A High Threshold For Noxious Heat", Nature 398, 436-441 (1999)). The channels are permeable to  
25 cations and exhibit a notable preference for divalent cations, particularly calcium ions. The level of calcium ion permeability exceeds that observed for most non-selective cation channels and is similar to values observed for NMDA-type glutamate receptors and alpha-7 nicotinic acetylcholine receptors.

**[0003]** Some polynucleotides encoding vanilloid receptors or vanilloid-like receptors have been cloned and identified (Caterina, M. J. et al., Nature 389, 816-824 (1997) and Caterina, M. J. et al., Nature 398, 436-441 (1999)). PCT  
30 Application International Publication No. WO 99/37675 discloses vanilloid receptor polypeptides and vanilloid receptor-related polypeptides, specifically the capsaicin receptor subtypes VR1 and VR2, and the encoding polynucleotide sequences. PCT Application International Publication NO. WO 99/37765 discloses VANILREP2 polypeptides and polynucleotides, recombinant materials and methods for their production.

**[0004]** If other subtypes of the capsaicin receptors were found and identified, it would be beneficial, for example, to  
35 use such subtypes to find novel ligands with respect to the capsaicin receptors.

**Brief Disclosure of the Invention**

**[0005]** The present invention provides a polypeptide selected from:

- 40 (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, or variants thereof; and  
(b) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence SEQ ID NO:1 or SEQ ID NO:3, or variants thereof.

45 **[0006]** Such polypeptides have been identified as novel human vanilloid receptor-like protein 2 polypeptides. As used herein, the novel human vanilloid receptor-like protein 2 is referred to as "VRL-2" or "VRL-2 protein". As used herein, these polypeptides can be referred to as "VRL-2 polypeptides" or "VRL-2 receptor polypeptides".

**[0007]** The present invention also provides an isolated and/or purified polynucleotide selected from:

- 50 (a) a polynucleotide encoding the polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;  
(b) a polynucleotide having a nucleotide sequence of the 85th to 2700th nucleotides in the nucleotide sequence of SEQ ID NO:1, or a nucleotide sequence of the 43rd to 1851st nucleotides in the nucleotide sequence of SEQ ID NO:3 or variants thereof;  
55 (c) a polynucleotide comprising a nucleotide sequence that has at least 70% identity to the polynucleotide of (a) or (b);  
(d) a complement to the polynucleotide of any one of (a) to (c);  
(e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); and

(f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).

**[0008]** The present invention also provides a polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide described above, or the complement thereof.

**[0009]** Further, the present invention provides an expression vector for the expression of the VRL-2 protein in a recombinant host cell wherein said expression vector contains the above DNA molecule, and a host cell which expresses a recombinant VRL-2 protein wherein said host cell contains the expression vector. Also provided is a process for producing the VRL-2 receptor polypeptides, which comprises culturing the host cell under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.

**[0010]** The VRL-2 receptor polypeptides, the VRL-2 receptor-encoding DNA, the expression vectors and recombinant host cells expressing recombinant VRL-2 are useful in the identification of modulators which modulate the function of the VRL-2 receptor. Thus, the present invention also provides a method for screening to identify modulators which modulate (e.g., bind) the VRL-2 receptor polypeptide, which comprises contacting the polypeptide with a test compound or sample, and detecting an activity of the compound or sample to modulate the function of the VRL-2 receptor polypeptide.

**[0011]** The present invention further provides a VRL-2 receptor modulator (e.g., agonist and antagonist) obtainable by the above screening method. These VRL-2 receptor modulators are useful for the treatment of diseases or conditions associated with the function of the VRL-2 receptor, or inappropriate VRL-2 receptor activity. Such diseases include pain, nociceptive pain, chronic pain, neuropathic pain, postoperative pain, cancer pain, rheumatoid arthritic pain, osteoarthritis, diabetic neuropathies, neuralgia, neuropathies, algesia, nerve injury, muscle-skeletal pain, low back pain, neurodegeneration, stroke, inflammatory disorders, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension, perivascular disease and the like.

**[0012]** Thus, the VRL-2 receptor modulators are useful in the treatment of such diseases. In addition, the VRL-2 receptor polypeptides and the VRL-2 receptor-encoding polynucleotides are also useful in diagnostic assays for detecting the VRL-2 receptor-related diseases.

**[0013]** The present invention further provides a diagnostic kit for diagnosing a disease or a susceptibility to a disease associated with biological function of a human vanilloid receptor-like protein, which comprises the above polynucleotides or an antibody to the VRL-2 receptor polypeptide.

**[0014]** In addition, the present invention provides an antibody immunospecific for the VRL-2 receptor polypeptides, and a non-human transgenic animal model for VRL-2 receptor gene function wherein the transgenic animal has an alteration in VRL-2 receptor function relative to a normal animal of the same species.

### **Brief Description of Figures**

**[0015]** Figs.1(A) and 1(B) show  $\text{Ca}^{2+}$  increase in hVRL-2 transfected CHO-K1 cells in response to a reduction in extracellular osmolarity.

**[0016]** Figs.2(A) and 2(B) show  $\text{Ca}^{2+}$  increase in hVRL-2 transfected HEK293 cells in response to a reduction in extracellular osmolarity.

### **Detailed Description of the Invention**

**[0017]** As used herein, the term "nucleotide sequence" refers to an oligonucleotide sequence or polynucleotide sequence, and variants, homologues, fragments and derivatives thereof (such as portions thereof). The nucleotide sequence may be DNA or RNA of genomic or synthetic or recombinant origin, which may be doublestranded or single-stranded whether representing the sense or antisense strand. Preferably, the term "nucleotide sequence" means DNA. More preferably, the term "nucleotide sequence" means DNA prepared by use of recombinant DNA techniques (i.e. recombinant DNA).

**[0018]** As used herein "amino acid sequence" refers to peptide or protein sequences or portions thereof.

**[0019]** As used herein, the terms "isolated" and "purified" refer to molecules, either nucleic or amino acid sequences, that are removed from their natural environment and isolated or separated from at least one other component with which they are naturally associated.

**[0020]** The terms "variant" in relation to the amino acid sequence for the preferred polypeptide of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one or more amino acids from or to the sequence providing the resultant polypeptide has VRL-2 activity.

**[0021]** The terms "variant" or "fragment" in relation to the nucleotide sequence coding for the preferred polypeptide of the present invention include any substitution of, variation of, modification of, replacement of, deletion of or addition of one or more nucleic acids from or to the sequence providing the resultant nucleotide sequence codes for or is capable of coding for a polypeptide having VRL-2 activity. Relative sequence homology (i.e. sequence identity) can be deter-

mined by commercially available computer programs that can calculate % homology between two or more sequences. A typical example of such a computer program is CLUSTAL.

[0022] The term "variant" encompasses sequences that are complementary to sequences that are capable of hybridising under stringent conditions (e.g. 65°C and 0.1xSSC {1xSSC = 0.15 M NaCl, 0.015 M Na<sub>3</sub> citrate pH 7.0}) to the nucleotide sequences presented herein.

[0023] The term "expression vector" means a construct capable of *in vivo* or *in vitro* expression.

[0024] As used herein, the term "antibodies" include polyclonal and monoclonal antibodies, chimeric, single chain and humanized antibodies. The term "immunospecific" means that the antibodies have substantially greater affinity for the polypeptides of the invention than their affinity for other related polypeptides.

[0025] The present invention will be further described below.

[0026] The present invention is based on the identification of a polynucleotide sequence encoding a novel human vanilloid receptor-like protein 2 (VRL-2) polypeptide. Such a polynucleotide has been isolated and purified, and the nucleotide sequence has been determined.

### VRL-2 Receptor Polypeptides

[0027] In a first aspect, the present invention provides a polypeptide selected from:

- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, or variants thereof; and
- (b) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence SEQ ID NO:1 or SEQ ID NO:3, or variants thereof.

[0028] The VRL-2 receptor polypeptides of the present invention are believed to be members of the ion channel family of polypeptides. The channels are permeable to cations and exhibit a notable preference for divalent cations, particularly calcium ions. The permeability of cations and the signal transmission ability of the VRL-2 receptors are affected by a ligand which modulates (e.g., binds, inhibits and activates) the function of the VRL-2 receptor polypeptides. These properties are hereinafter referred to as "VRL-2 receptor activities".

[0029] Preferably, the polypeptide or variants comprises an amino acid sequence that has at least 75% (more preferably at least 85%, even more preferably at least 95%) identity to the amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4. The variants preferably show at least one of the above-mentioned VRL-2 activities. More specifically, the polypeptides may vary from the referents by conservative amino acid substitutions, whereby a residue is substituted by another with the VRL-2 activity. Such substitutions may be made among Ala, Val, Leu and Ile; among Ser and Thr; among the acidic residues Asp and Glu; among Asn and Gln; and among the basic residues Lys and Arg; or aromatic residues Phe and Tyr. Thus, this invention includes variants of the polypeptides where 1 to 10, more preferably 1 to 5, further preferably 1 to 3, further preferably 1 to 2 or most preferably 1 amino acid(s) are substituted, deleted, or added in any combination in the amino acid sequence of SEQ ID NO:2 or NO:4.

[0030] The polypeptides of the present invention may be in the form of the "mature" protein or may be a part of a larger protein such as a precursor or a fusion protein. It is often advantageous to include an additional amino acid sequence which contains secretory or leader sequences, prosequences, sequences which aid in purification such as multiple histidine residues, or an additional sequence for stability during recombinant production.

[0031] Polypeptides of the present invention can be prepared in any suitable manner. Such polypeptides include isolated naturally occurring polypeptides, recombinantly produced polypeptides, synthetically produced polypeptides, or polypeptides produced by a combination of these methods. Means for preparing such polypeptides are well understood in the art. The VRL-2 receptor polypeptides of this invention can be prepared using DNA molecules encoding the amino acid sequence of the polypeptides.

### Polynucleotides/DNA molecules

[0032] In a further aspect, the present invention relates to an isolated and/or purified polynucleotide selected from:

- (a) a polynucleotide encoding the polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
- (b) a polynucleotide having a nucleotide sequence of the 85th to 2700th nucleotides in the nucleotide sequence of SEQ ID NO:1, or a nucleotide sequence of the 43rd to 1851st nucleotides in the nucleotide sequence of SEQ ID NO:3 or variants thereof;
- (c) a polynucleotide comprising a nucleotide sequence that has at least 70% identity to the polynucleotide of (a) or (b);
- (d) a complement to the polynucleotide of any one of (a) to (c);
- (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any

one of (a) to (d); and

(f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).

**[0033]** Preferably, the polynucleotide comprises a nucleotide sequence that has at least 75% (more preferably at least 85%, yet more preferably at least 95%) identity to the nucleotide sequence of the above polynucleotide (b).

**[0034]** The nucleotide sequences of SEQ ID NO: 1 and SEQ ID NO:3 show homology with rat vanilloid receptor 1 (VR1) (M. J. Caterina et al., Nature 389: 816-824, 1997), rat/human vanilloid receptor like protein 1 (VRL-1) (M. J. Caterina et al., Nature 398: 436-441, 1999), rat stretch-activated channel (SIC) (J. Biol. Chem. 274: 6330-6335, 1999) and mouse growth-factor-regulated channel (GRC) (Nature Cell Biol. 1: 165-170). The nucleotide sequences of SEQ ID NO:1 and SEQ ID NO:3 were found to be full length of cDNA encoding the VRL-2a and VRL-2b polypeptides, respectively. Similarities of human VRL-2a with rat VR1, rat VRL-1, human VRL-1, rat SIC and mouse GRC in amino acid sequence were 51%, 46%, 47%, 59% and 47%, respectively. Similarities of human VRL-2b with rat VR1, rat VRL-1, human VRL-1, rat SIC and mouse GRC in amino acid sequence were 50%, 45%, 46%, 59% and 45%, respectively. VR1 is heat, proton and capsaicin-activated cation channel. Rat VRL-1 is heat-activated cation channel. Rat SIC is mechano-sensitive cation channel. Mouse GRC is IGF-1-regulated cation channel. Accordingly, both human VRL-2a and VRL-2b are predicted to be cation channels activated by stimuli such as heat, proton, chemicals, mechano-stimulation of membrane, growth factor.

**[0035]** The polynucleotides (DNA molecules) of the present invention may be obtained, using standard cloning and screening techniques, from a cDNA library derived from mRNA in cells of human placenta, brain, heart, melanocyte, liver, spleen, foreskin, lung, parathyroid, tonsil, whole embryo, Jurkat T-cells, B-cells and testes (for example Sambrook et al., Molecular Cloning: A Laboratory Manual, 2nd Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.(1989)). The DNA molecules of the invention can also be obtained from natural sources such as genomic DNA libraries or can be synthesized using well known and commercially available techniques.

**[0036]** Other cells and cell lines may also be suitable for use to isolate VRL-2 cDNA. Selection of suitable cells may be done by screening for VRL-2 on cell surfaces. Methods for detecting VRL-2 activity are well known in the art and measure the binding of radiolabelled ligand specific for the receptor. Cells which possess VRL-2 activity in this assay may be suitable for the isolation of VRL-2 cDNA.

**[0037]** Any of a variety of procedures may be used to clone VRL-2 cDNA. These methods include, but are not limited to, direct functional expression of the VRL-2 cDNA following the construction of an VRL-2-containing cDNA library in an appropriate expression vector system. Another method is to screen an VRL-2-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a labelled oligonucleotide probe designed from the amino acid sequence of the VRL-2 protein. The preferred method includes screening an VRL-2-containing cDNA library constructed in a bacteriophage or plasmid shuttle vector with a partial cDNA encoding the VRL-2 protein. This partial cDNA is obtained by the specific PCR amplification of VRL-2 DNA fragments through the design of degenerate oligonucleotide primers from the amino acid sequence known for other capsaicin receptors.

**[0038]** It is readily apparent to those skilled in the art that other types of libraries, as well as libraries constructed from other cells or cell types, may be useful for isolating VRL-2-encoding DNA. Other types of libraries include, but are not limited to, cDNA libraries derived from other cells or cell lines other than human erythroleukemia cells, and genomic DNA libraries.

**[0039]** It is readily apparent to those skilled in the art that suitable cDNA libraries may be prepared from cells or cell lines which have VRL-2 activity. The selection of cells or cell lines for use in preparing a cDNA library to isolate VRL-2 cDNA may be done by first measuring cell associated VRL-2 activity using the known labelled ligand binding assay cited above and used herein.

**[0040]** Preparation of cDNA libraries can be performed by standard techniques well known in the art. Well known cDNA library construction techniques can be found for example, in Maniatis, T., Fritsch, E. F., Sambrook, J., Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982).

**[0041]** It is also readily apparent to those skilled in the art that DNA encoding VRL-2 may also be isolated from a suitable genomic DNA library. Construction of genomic DNA libraries can be performed by standard techniques well known in the art. Well known genomic DNA library construction techniques can be found in Maniatis, T., Fritsch, E. F., Sambrook, J. in Molecular Cloning: A Laboratory Manual (Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y., 1982).

**[0042]** In order to clone the VRL-2 gene by one of the preferred methods, the amino acid sequence or DNA sequence of VRL-2 or a homologous protein is necessary. To accomplish this, VRL-2 protein or a homologous protein may be purified and partial amino acid sequence determined by automated sequencers. It is not necessary to determine the entire amino acid sequence, but the linear sequence of two regions of 6 to 8 amino acids can be determined for the PCR amplification of a partial VRL-2 DNA fragment.

**[0043]** Once suitable amino acid sequences have been identified, the DNA sequences capable of encoding them are synthesized. Because the genetic code is degenerate, more than one codon may be used to encode a particular

amino acid, and therefore, the amino acid sequence can be encoded by any of a set of similar DNA oligonucleotides. Only one member of the set will be identical to the VRL-2 sequence but others in the set will be capable of hybridizing to VRL-2 DNA even in the presence of DNA oligonucleotides with mismatches. The mismatched DNA oligonucleotides may still sufficiently hybridize to the VRL-2 DNA to permit identification and isolation of VRL-2 encoding DNA.

5 [0044] Using one of the preferred methods, cDNA clones encoding VRL-2 polypeptide are isolated in a two-stage approach employing polymerase chain reaction (PCR) based technology and cDNA library screening. In the first stage, NH.sub.2-terminal and internal amino acid sequence information from the purified VRL-2 or a homologous protein is used to design degenerate oligonucleotide primers for the amplification of VRL-2-specific DNA fragments. In the second stage, these fragments are cloned to serve as probes for the isolation of full length cDNA from a cDNA library derived from human erythroleukemia cells.

10 [0045] The polynucleotides of the present invention may be used as hybridization probes for cDNA and genomic DNA or as primers for a nucleic acid amplification (PCR) reaction, to isolate full-length cDNAs and genomic clones encoding polypeptides of the present invention and to isolate cDNA and genomic clones of other genes (including genes encoding paralogs from human sources and orthologs and paralogs from species other than human) that have a high sequence similarity to SEQ ID NO:1 or SEQ ID NO:3.

[0046] The probes or primers of the present invention generally comprise at least 15 nucleotides, preferably, at least 30 nucleotides and may have at least 50 nucleotides. Particularly preferred probes will have between 30 and 50 nucleotides. Particularly preferred primers will have between 20 and 25 nucleotides.

20 [0047] A polynucleotide encoding a polypeptide of the present invention, including homologs from species other than human, may be obtained by a process which comprises the steps of screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:3 or a fragment thereof and isolating full-length cDNA and genomic clones containing said polynucleotide sequence. Such hybridization techniques are well known to the skilled artisan. Preferred stringent hybridization conditions include overnight incubation at 42°C in a solution comprising: 50% formamide, 5xSSC (150mM NaCl, 15mM trisodium citrate), 50 mM sodium phosphate (pH7.6), 5x Denhardt's solution, 10% dextran sulfate, and 20 microgram/ml denatured, sheared salmon sperm DNA; followed by washing the filters in 0.1 x SSC at about 65°C. Thus the present invention also includes polynucleotides obtainable by screening an appropriate library under stringent hybridization conditions with a labeled probe having the sequence of SEQ ID NO:1 or SEQ ID NO:3, or a fragment thereof.

30 [0048] The skilled artisan will appreciate that, in many cases, an isolated cDNA sequence will be incomplete, in that the region coding for the polypeptide is short at the 5' end of the cDNA. This is a consequence of reverse transcriptase, an enzyme with inherently low 'processivity' (a measure of the ability of the enzyme to remain attached to the template during the polymerization reaction), failing to complete a DNA copy of the mRNA template during 1st strand cDNA synthesis.

35 [0049] There are several methods available and well known to those skilled in the art to obtain full-length cDNAs, or extend short cDNAs, for example those based on the method of Rapid Amplification of cDNA ends (RACE) (see, for example, Frohman et al., PNAS USA 85, 8998-9002, 1988). Recent modifications of the technique, exemplified by the Marathon™ technology (Clontech Laboratories Inc.) for example, have significantly simplified the search for longer cDNAs.

#### 40 Expression Vectors

[0050] Recombinant VRL-2 polypeptides of the present invention may be prepared by processes well known in the art from genetically engineered host cells comprising expression vectors. Accordingly, the present invention relates to an expression vector for the expression of a human vanilloid receptor-like protein in a recombinant host cell wherein said expression vector contains the above-identified DNA molecule.

45 [0051] The cloned VRL-2 cDNA obtained through the methods described above may be recombinantly expressed by molecular cloning into an expression vector containing a suitable promoter and other appropriate transcription regulatory elements, and transferred into prokaryotic or eukaryotic host cells to produce recombinant VRL-2 polypeptides. Techniques for such manipulations can be found described in Maniatis, T, et al., supra, and are well known in the art.

50 [0052] Expression vectors are defined herein as DNA sequences that are required for the transcription of cloned DNA and the translation of their mRNAs in an appropriate host. Such vectors can be used to express eukaryotic DNA in a variety of hosts such as bacteria, bluegreen algae, plant cells, insect cells and animal cells.

55 [0053] Specifically designed vectors allow the shuttling of DNA between hosts such as bacteria-yeast or bacteria-animal cells. An appropriately constructed expression vector should contain an origin of replication for autonomous replication in host cells, selectable markers, a limited number of useful restriction enzyme sites, a potential for high copy number, and active promoters. A promoter is defined as a DNA sequence that directs RNA polymerase to bind to DNA and initiate RNA synthesis. A strong promoter is one which causes mRNAs to be initiated at high frequency. Expression vectors may include, but are not limited to, cloning vectors, modified cloning vectors, specifically designed

plasmids or viruses.

**[0054]** A variety of mammalian expression vectors may be used to express recombinant VRL-2 in mammalian cells. Commercially available mammalian expression vectors which may be suitable for recombinant VRL-2 expression, include but are not limited to, pMCIneo (Stratagene), pXT1 (Stratagene), pSG5 (Stratagene), pcDNA1, pcDNA3.1 (Invitrogen), EBO-pSV2-neo (ATCC 37593) pBPV-1(8-2) (ATCC 37110), pdBPV-MMTneo(342-12) (ATCC 37224), pRSVgpt (ATCC 37199), pRSVneo (ATCC 37198), pSV2-dhfr (ATCC 37146), pUCtag (ATCC 37460), and IZD35 (ATCC 37565).

#### **Host Cells Containing Expression Vector**

**[0055]** DNA encoding the VRL-2 polypeptide may also be cloned into an expression vector for expression in a host cell. Host cells may be prokaryotic or eukaryotic, including but not limited to bacteria, fungal, insect, animal (including mammalian) and plant cells. Suitable bacterial cells include *Streptococci*, *Staphylococci*, *E. coli*, *Streptomyces* and *Bacillus subtilis* cells. Suitable fungal cells include yeast cells and *Aspergillus* cells. The animal cells include cell lines of human, bovine, porcine, monkey and rodent origin. Suitable insect cells include *Drosophila* S2 and *Spodoptera* Sf9 cells. Suitable animal cells include CHO, COS, HeLa, C127, 3T3, BHK, HEK 293 and Bowes melanoma cells. Cell lines derived from mammalian species which may be suitable and which are commercially available, include CV-1 (ATCC CCL 70), COS-1 (ATCC CRL 1650), COS-7 (ATCC CRL 1651), CHO-K1 (ATCC CCL 61), 3T3 (ATCC CCL 92), NIH/3T3 (ATCC CRL 1658), HeLa (ATCC CCL 2), C1271 (ATCC CRL 1616), BS-C-1 (ATCC CCL 26) and MRC-5 (ATCC CCL 171).

**[0056]** The expression vector may be introduced into host cells via any one of a number of techniques including but not limited to transformation, transfection, protoplast fusion, and electroporation. The expression vector-containing cells are individually analyzed to determine whether they produce VRL-2 protein. Identification of VRL-2 expressing cells may be done by several means, including but not limited to immunological reactivity with anti-VRL-2 antibodies, and the presence of host cell-associated VRL-2 activity.

**[0057]** Expression of VRL-2 DNA may also be performed using in vitro produced synthetic mRNA. Synthetic mRNA can be efficiently translated in various cell-free systems, including but not limited to wheat germ extracts and reticulocyte extracts, as well as efficiently translated in cell based systems, including but not limited to microinjection into frog oocytes, with microinjection into frog oocytes being preferred.

**[0058]** To determine the VRL-2 cDNA sequence(s) that yields optimal levels of receptor activity and/or VRL-2, VRL-2 cDNA molecules including but not limited to the following can be constructed: the full-length open reading frame of the VRL-2 cDNA and various constructs containing portions of the cDNA encoding only specific domains of the receptor protein or rearranged domains of the protein. All constructs can be designed to contain none, all or portions of the 5' and/or 3' untranslated region of VRL-2 cDNA. VRL-2 activity and levels of protein expression can be determined following the introduction, both singly and in combination, of these constructs into appropriate host cells. Following determination of the VRL-2 cDNA cassette yielding optimal expression in transient assays, this VRL-2 cDNA construct is transferred to a variety of expression vectors (including recombinant viruses), including but not limited to those for mammalian cells, plant cells, insect cells, oocytes, *E. Coli*, and yeast cells.

**[0059]** Mammalian cell transfectants are assayed for both the levels of VRL-2 receptor activity and levels of VRL-2 protein by the following methods. Assessing VRL-2 receptor activity involves the direct introduction of a labelled ligand to the cells and determining the amount of specific binding of the ligand to the VRL-2-expressing cells. Binding assays for receptor activity are known in the art (Frey et al., 1993, Eur. J. Pharmacol., 244, pp 239-250).

**[0060]** Levels of VRL-2 protein in host cells is quantitated by a variety of techniques including, but not limited to, immunoaffinity and/or ligand affinity techniques. VRL-2-specific affinity beads or VRL-2-specific antibodies are used to isolate <sup>35</sup>S-methionine labelled or unlabelled VRL-2 protein. Labelled VRL-2 protein is analyzed by SDS-PAGE. Unlabelled VRL-2 protein is detected by Western blotting, ELISA or RIA assays employing VRL-2 specific antibodies.

**[0061]** Following expression of VRL-2 in a host cell, VRL-2 protein may be recovered to provide VRL-2 in active form, capable of binding VRL-2-specific ligands. Several VRL-2 purification procedures are available and suitable for use.

**[0062]** Recombinant VRL-2 may be purified from cell lysates and extracts, or from conditioned culture medium, by various combinations of, or individual application of salt fractionation, ion exchange chromatography, size exclusion chromatography, hydroxylapatite adsorption chromatography and hydrophobic interaction chromatography. □

**[0063]** Thus, the present invention also provides a process for producing the VRL-2 receptor polypeptides, which comprises culturing a host cell comprising the expression vector containing the above DNA molecule under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium. The conditions for producing the polypeptides can be easily designed by a skilled person. Well known techniques for refolding proteins may be employed to regenerate active conformation when the polypeptide is denatured during intracellular synthesis,

isolation and or purification.

### **Antibodies**

**[0064]** The present invention further provides antibodies immunospecific for the VRL-2 receptor polypeptide.

**[0065]** The antibodies may be obtained by administering the polypeptides or epitope-bearing fragments, analogs or cells to an animal, preferably a non-human animal, according to known techniques. For preparation of monoclonal antibodies, any technique which provides antibodies produced by continuous cell line cultures can be used. Examples include the hybridoma technique (Kohler, G. and Milstein, C., Nature (1975) 256:495-497), the trioma technique, the human B-cell hybridoma technique (Kozboret al., Immunology Today (1983) 4:72) and the EBV-hybridoma technique (Cole et al., Monoclonal Antibodies and Cancer Therapy 77-96, Alan R. Liss, Inc., 1985). Techniques for the production of single chain antibodies, such as those described in U.S. Patent No. 4,946,778, can also be adapted to produce single chain antibodies to polypeptides of this invention. Also, transgenic mice, or other organisms, including other mammals, may be used to express humanized antibodies. The above-described antibodies may be employed to isolate or to identify clones expressing the polypeptide or to purify the polypeptides by affinity chromatography. Antibodies against polypeptides of the present invention may also be employed to treat the diseases, amongst others.

### **Diagnostic Tool**

**[0066]** The DNA molecules of the present invention can be used as diagnostic reagents. Detection of a mutated form of the gene characterized by the polynucleotide of this invention, which is associated with a dysfunction, will provide a diagnostic tool that can add to, or define, a diagnosis of a disease, or susceptibility to a disease, which results from under-expression, over-expression or altered spatial or temporal expression of the gene. Individuals carrying mutations in the gene may be detected at the DNA level by a variety of techniques.

**[0067]** Nucleic acids for diagnosis may be obtained from a subject's cells, such as from blood, urine, saliva tissue biopsy or autopsy material. The genomic DNA may be used directly for detection or may be amplified enzymatically by using PCR or other amplification techniques prior to analysis. RNA or cDNA may also be used in similar fashion. Deletions and insertions can be detected by a change in size of the amplified product in comparison to the normal genotype. Point mutations can be identified by hybridizing amplified DNA to labeled VRL-2 nucleotide sequences. Perfectly matched sequences can be distinguished from mismatched duplexes by RNase digestion or by differences in melting temperatures. DNA sequence differences may also be detected by alterations in electrophoretic mobility of DNA fragments in gels, with or without denaturing agents, or by direct DNA sequencing (see, e.g., Myers et al., Science (1985) 230: 1242).

**[0068]** Sequence changes at specific locations may also be revealed by nuclease protection assays, such as RNase and S I protection or the chemical cleavage method (see Cottonet al., Proc Nati Acad Sci USA (1985) 85: 4397-4401). In another embodiment, an array of oligonucleotides probes comprising VRL-2 nucleotide sequence or fragments thereof can be constructed to conduct efficient screening of e.g., genetic mutations. Array technology methods are well known and have general applicability and can be used to address a variety of questions in molecular genetics including gene expression, genetic linkage, and genetic variability (see for example: M.Chee et al., Science, Vol 274, pp 610-613 (1996)).

**[0069]** The diagnostic assays offer a process for diagnosing or determining a susceptibility to the VRL-2 related diseases through detection of mutation in the VRL-2 gene by the methods described. In addition, such diseases may be diagnosed by methods comprising determining from a sample derived from a subject an abnormally decreased or increased level of polypeptide or mRNA. Decreased or increased expression can be measured at the RNA level using any of the methods well known in the art for the quantitation of polynucleotides, such as, for example, nucleic acid amplification, for instance PCR, RT-PCR. RNase protection, Northern plotting and other hybridization methods. Assay techniques that can be used to determine levels of a protein, such as a polypeptide of the present invention, in a sample derived from a host are well-known to those of skill in the art. Such assay methods include radioimmunoassays, competitive-binding assays, Western Blot analysis and ELISA assays.

**[0070]** In another aspect, the present invention relates to a diagnostic kit which comprises the DNA molecule of the present invention or an antibody to the polypeptide of the present invention. If desired, the diagnostic kit can comprise other materials which can be used in known diagnostic kits. Such a kit can be used in diagnosing a disease or susceptibility to a disease, particularly pain, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, algnesia, nerve injury, ischaemia, neurodegeneration, stroke, incontinence and inflammatory disorders, amongst others.



**Screening Methods**

[0071] The novel VRL-2 receptor of the present invention is suitable for use in an assay procedure for identification of modulators which modulate the function of the VRL-2 receptor activity. Thus, this invention also provides a method for screening modulators which modulate the function of the VRL-2 polypeptides. As used herein, "modulating function of a receptor" or "modulating receptor activity" includes the inhibition or activation of the receptor, and also includes directly or indirectly affecting the normal regulation of the receptor activity. As used herein, the term "modulator" means compounds, agonists, antagonists, ligands, substrates and enzymes which directly or indirectly affect regulation of the receptor activity.

[0072] The VRL-2 receptor of the present invention may be obtained from both native and recombinant sources for use in an assay procedure to identify receptor modulators. In general, an assay procedure to identify VRL-2 receptor modulators may comprise contacting the VRL-2 polypeptide (or the cells or membranes bearing the polypeptide) of the present invention with a test compound or sample which expects to contain a VRL-2 receptor modulator, and detecting an activity to modulate the function of the VRL-2 receptor (e.g., binding activity). The test compounds or samples may be tested directly on, for example, purified receptor, subcellular fractions of receptor-producing cells, and/or whole cells expressing the receptor. The test compound or sample may be added to the receptor in the presence or absence of a known labelled or unlabelled receptor ligand. Further, these screening methods may test whether the candidate compound results in a signal generated by activation or inhibition of the polypeptide, using detection systems appropriate to the cells bearing the polypeptide. The modulating activity of the test compound or sample may be determined by, for example, analyzing the ability of the test compound or sample to bind to the receptor, activate the receptor, inhibit receptor activity, inhibit or enhance the binding of other compounds to the receptor, modifying receptor regulation, or modifying an intracellular activity.

[0073] The other known screening methods can be used in this invention. Such known methods can be found in PCT International Publication No. WO 99/37765, Page 13, Line 5 to Page 14, Line 31. In addition, the screening method of this invention covers a counter-assay to identify a certain compound which does not have a VRL-2 modulating activity.

[0074] The above-mentioned screening method can be practiced by use of a screening kit for identifying modulators for polypeptides of the present invention, which comprises (a) a polypeptide of the present invention; (b) a recombinant cell expressing a polypeptide of the present invention; or (c) a cell membrane expressing a polypeptide of the present invention. Any known materials or components which can be used for a screening kit can be added to the screening kit of this invention.

[0075] The modulators of VRL-2 receptor activity are useful in treating disease states involving the VRL-2 receptor activity as mentioned above.

**Pharmaceutical Composition**

[0076] The present invention further provides a pharmaceutical composition for treatment of conditions associated with biological function of a human vanilloid receptor-like protein, which comprises a therapeutically effective amount of a modulator (e.g., agonist or antagonist) obtained by the above-mentioned screening methods and a pharmaceutically acceptable carrier. The conditions associated with biological function of the VRL-2 receptor include pain, nociceptive pain, chronic pain, neuropathic pain, postoperative pain, cancer pain, rheumatoid arthritic pain, osteoarthritis, diabetic neuropathies, neuralgia, neuropathies, algnesia, nerve injury, muscle-skeletal pain, low back pain, neurodegeneration, stroke, inflammatory disorders, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension, perivascular disease and the like. Thus, the pharmaceutical compositions of this invention are useful as drugs for treating such diseases.

[0077] The pharmaceutical composition of this invention can be administered via either the oral, parenteral or topical routes to mammals. In general, these compounds are most desirably administered to humans in doses ranging from 0.1 mg to 750 mg per day, preferably from 10 mg to 500 mg per day, although variations will necessarily occur depending upon the weight and condition of the subject being treated, the disease state being treated and the particular route of administration chosen.

[0078] The compounds of the present invention may be administered alone or in combination with pharmaceutically acceptable carriers or diluents by either of the above routes previously indicated, and such administration can be carried out in single or multiple doses. More particularly, the novel therapeutic agents of the invention can be administered in a wide variety of different dosage forms, i.e., they may be combined with various pharmaceutically acceptable inert carriers in the form of tablets, capsules, lozenges, troches, hard candies, powders, sprays, creams, salves, suppositories, jellies, gels, pastes, lotions, ointments, aqueous suspensions, injectable solutions, elixirs, syrups, and the like. Such carriers include solid diluents or fillers, sterile aqueous media and various nontoxic organic solvents, etc. Moreover, oral pharmaceutical compositions can be suitably sweetened and/or flavored. In general, the therapeutically-effective compounds of this invention are present in such dosage forms at concentration levels ranging 5% to 70% by

weight, preferably 10% to 50% by weight.

**[0079]** For oral administration, tablets containing various excipients such as microcrystalline cellulose, sodium citrate, calcium carbonate, dipotassium phosphate and glycine may be employed along with various disintegrants such as starch and preferably corn, potato or tapioca starch, alginic acid and certain complex silicates, together with granulation binders like polyvinylpyrrolidone, sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often very useful for tableting purposes. Solid compositions of a similar type may also be employed as fillers in gelatine capsules; preferred materials in this connection also include lactose or milk sugar as well as high molecular weight polyethylene glycols. When aqueous suspensions and/or elixirs are desired for oral administration, the active ingredient may be combined with various sweetening or flavoring agents, coloring matter or dyes, and, if so desired, emulsifying and/or suspending agents as well, together with such diluents as water, ethanol, propylene glycol, glycerin and various like combinations thereof.

**[0080]** For parenteral administration, solutions of a compound of the present invention in either sesame or peanut oil or in aqueous propylene glycol may be employed. The aqueous solutions should be suitably buffered (preferably pH>8) if necessary and the liquid diluent first rendered isotonic. These aqueous solutions are suitable for intravenous injection purposes. The oily solutions are suitable for intra-articular, intra-muscular and subcutaneous injection purposes. The preparation of all these solutions under sterile conditions is readily accomplished by standard pharmaceutical techniques well-known to those skilled in the art. Additionally, it is also possible to administer the compounds of the present invention topically when treating inflammatory conditions of the skin and this may preferably be done by way of creams, jellies, gels, pastes, ointments and the like, in accordance with standard pharmaceutical practice.

### Transgenic Animals

**[0081]** The polypeptides and/or DNA molecules of the present invention can be used to generate genetically modified non-human animals or site specific gene modifications in cell lines. The term "transgenic" is intended to encompass genetically modified animals having, for example, a deletion or other knock-out of VRL-2 receptor gene activity, an exogenous VRL-2 receptor gene that is stably transmitted in the host cells, a "knock-in" having altered VRL-2 receptor gene expression, or an exogenous VRL-2 receptor polypeptide promoter operably linked to a reporter gene. Homozygous and heterozygous knock-outs and knock-ins of VRL-2 receptor polypeptide function are particularly preferred.

**[0082]** Transgenic animals can be made according to methods known to skilled persons in the art. For example, the transgenic animals may be made through homologous recombination, where the endogenous VRL-2 receptor locus is altered. Alternatively, a nucleic acid construct is randomly integrated into the genome. Vectors for stable integration include plasmids, retroviruses and other animal viruses, YACs, and the like. Of interest are transgenic mammals, preferably a mammal from a genus selected from the group consisting of *Mus* (e.g., mice), *Rattus* (e.g., rats), *Oryctolagus* (e.g., rabbits) and *Mesocricetus* (e.g., hamsters). More specific descriptions about preparation and use of the transgenic animals can be found in WO 99/37675, Page 34, Line 36 to Page 37, Line 12.

### EXAMPLES

**[0083]** The following examples are provided for the purpose of illustrating the present invention without, however, limiting the same thereto.

#### Example 1: Cloning of h VRL-2 cDNA

**[0084]** A BLAST search against LifeSeq™ database (Incyte) was made, using the polynucleotide and polypeptide sequences of the rat vanilloid receptor subtype 1 (hereinafter referred to as "VR1"). Six cDNA clones were obtained that contained nucleotide sequences highly homologous to the rat VR1. Five clones out of six were human homologs of rat VR1 or human vanilloid receptor-like protein 1 (hereinafter referred to as "VRL-1"). However, one cDNA clone did not match either of VR1 or VRL-1, and encoded a novel human receptor homologous to vanilloid receptor subtypes. This cDNA was designated as "VRL-2". This cDNA clone did not contain the entire open reading frame.

**[0085]** Further, a full-length cDNA cloning of human VRL-2 was performed. To identify start codon of VRL-2, two primers (5'-GCT GTC GGG GAA GAG GCG GGC ACA CTT G-3' and 5'-GCA GCA GTT CAT TGA TGG GCT CCA CAG C) designed from the sequence data of Incyte clone and human pancreas Marathon-Ready™ cDNA (Clontech, Palo Alto, Calif.) were used. 5' rapid amplification of cDNA ends (5'RACE) was performed under the following conditions: 94°C for 1 min and 68°C for 2 min, 30 cycles. The amplified 1.1 Kb RACE product were cloned and sequenced by automated DNA sequencer ABI PRISM 310 (PE Biosystems, Foster City, Calif.) produced by TOYOBO. These sequence data showed that 5'RACE products contained two kinds of 5' portion that possess a potential initiator codon downstream of an in-frame termination codon. VRL-2 constituted a subfamily that contained at least two spliced vari-

ants. One clone was designated as VRL-2a, and the other was designated as VRL-2b.

[0086] To isolate complete open reading frame of VRL2a and VRL-2b, PCR was performed using Advantage-HF PCR Kit (Clontech, Palo Alto, Calif.) and human kidney cDNA library (Clontech, Palo Alto, Calif.). Two sets of primers were designed from sequence data of 5'RACE products and Incyte clone; VRL-2a Forward 5'-ATC TGC GCA TGA AGTTCC AG-3', VRL-2b Forward 5'-GAC ATC GCG GAG CGC ACC GGC AAC ATG-3' and VRL-2a,b Reverse 5'-GCT GGA CTA GAA ATG AGT GGG CAG AGA A. PCR was performed under the following conditions: 94°C for 20 sec, 58°C for 30 sec and 72°C for 30 sec, 25 cycles. PCR products of 2.6 kb (VRL-2a) and 1.9 kb (VRL-2b) were cloned and sequenced by automated DNA sequencer ABI PRISM 310 (PE Biosystems, Foster City, Calif.; produced by TOYOBO Gene Analysis. The amino acid sequences of VRL-2a and VRL-2b are shown in SEQ ID NO:2 and SEQ ID NO:4, respectively.

### **Example 2: Expression of hVRL-2 in Mammalian Cells**

[0087] A cDNA encoding human VRL2a was subcloned into the eukaryotic expression vector pcDNA3.1 (Invitrogen). CHO-K1 cells and HEK 293 cells were plated onto poly-1-lysine coated glass-bottom dishes and transiently transfected with expression vector and pIRES2-EGFP (Clontech) (total 1.0 µg) and 3 µl FuGENE6 transfection reagent (Roche) in 97 µl of OptiMEM medium (Life Technologies) per 35mm dish.

### **Example 3: Functional Analysis of hVRL-2**

[0088] Activities of VRL-2 as a cation channel are readily detected with fluorescent dyes and conventional microscopy. The VRL-2-expressing cells (as obtained in Example 2) plated on glass coverslips are loaded with calcium indicators such as fura-2 or fluo-3, or a membrane potential indicator DiBAC4 in Hank's balanced salt buffer. The osmotic, mechanical or thermal stimuli are applied to the VRL-2-expressing cells loaded with the fluorescent dyes, and changes in fluorescence are monitored by a single cell imaging system mounted on an inverted fluorescence microscopy.

[0089] In this example, Ca<sup>2+</sup> measurements were carried out for 24 to 48 hours after transfection. Ca<sup>2+</sup> measurements in single cells were made using the fluorescent Ca<sup>2+</sup> indicator fura-2 in combination with a fluorescence imaging system MERLIN (OLYMPUS) mounted on an inverted fluorescence microscopy (IX70, OLYMPUS). For Ca<sup>2+</sup> imaging, cells were loaded with 5 µM fura-2 acetoxymethylester (Dojin) for 30 min at room temperature in isotonic (300 mosmol l<sup>-1</sup>) measuring buffer containing 88 mM NaCl, 5 mM KCl, 1 mM MgCl<sub>2</sub>, 1 mM CaCl<sub>2</sub>, 5.5 mM glucose and 10 mM HEPES at pH7.4. The osmolarity was adjusted by addition of appropriate amounts of mannitol. A sequence of fluorescent images (340 nm/380 nm excitation) was taken to monitor Ca<sup>2+</sup> influx response in cells with or without expression of GFP before and after the osmotic change. Cells were initially kept in isotonic solution. Hypotonic challenge was achieved by perfusion with 200 mosmol l<sup>-1</sup> measuring buffer. The solution of lower osmolarity was obtained by reducing the mannitol concentration. The effective assay buffer volume was 2 ml, and perfusion was carried out at room temperature at a flow rate of 3 ml min<sup>-1</sup>. Complete exchange of the perfusion solution was assumed after 2 min. Non-transfected cells were used as controls. Other control experiments were carried out using cells transfected with pcDNA3.1.

[0090] The results of the experiments can be seen in Figs 1(A), 1(B), 2(A) and 2(B).

[0091] Figs.1(A) and 1(B) show Ca<sup>2+</sup> increase in hVRL-2 transfected CHO-K1 cells in response to a reduction in extracellular osmolarity. In Fig. 1(A), Lines 1 and 2 show response curves of cells without expression vectors (Mock transfection). In Fig. 1(B), Line 1 shows a response curve of a GFP-negative cell (non-transfected cell), and Line 2 shows a response curve of a GFP-positive cell (hVRL-2a transfected cell).

[0092] Figs.2(A) and 2(B) show Ca<sup>2+</sup> increase in hVRL-2 transfected HEK293 cells in response to a reduction in extracellular osmolarity. In Fig. 2(A), Lines 1 and 2 show response curves of cells without expression vectors (Mock transfection). In Fig. 2(B), Line 1 shows a response curve of a GFP-negative cell (non-transfected cell), and Line 2 shows a response curve of a GFP-positive cell (hVRL-2a transfected cell).

[0093] As can be seen in these Figures, upon reduction of extracellular osmolarity, intracellular Ca<sup>2+</sup> increased significantly in the hVRL2a transfected cells, but not in control cells. This response was reversible, and increasing the osmolarity led to a decrease in intracellular Ca<sup>2+</sup>.

[0094] All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth. In particular, the definition of technical terms described in WO 99/37765 can be used as reference.

Annex to the application documents - subsequently filed sequences listing

[0095]

```

5
    <210> 5
    <211> 28
    <212> DNA
    <213> Homo sapiens

10
    <400> 5
    gctgtcgggg aagaggcggg cacacttg

    <210> 6
    <211> 28
    <212> DNA
    <213> Homo sapiens

15
    <400> 6
    gcagcagttc attgatgggc tccacagc

20
    <210> 7
    <211> 20
    <212> DNA
    <213> Homo sapiens

25
    <400> 7
    atctgcgcac gaagttccag

    <210> 8
    <211> 27
    <212> DNA
    <213> Homo sapiens

30
    <400> 8
    gacatcgagg agcgacccgg caacatg

35
    <210> 9
    <211> 28
    <212> DNA
    <213> Homo sapiens

40
    <400> 9
    gctggactag aatgagtgg gcagagaa

45

50

55

```

# EP 1 160 254 A1

## SEQUENCE LISTING (which forms part of the description)

<110> Pfizer, Inc.

<120> Human Vanilloid Receptor-Like Proteins

<130> PC9979A

<140>

<141>

<150> US 60/208,156

<151> 2000-05-31

<160> 4

<170> PatentIn Ver. 2.1

<210> 1

<211> 2749

<212> DNA

<213> Human

<220>

<221> CDS

<222> (85)..(2700)

<400> 1

aaccgcttga ggattttaagc tttgccactt tggtctccgga gcaagggcag agggctgagc 60

agtgcagacg ggcctggggc aggc atg gcg gat tcc agc gaa ggc ccc cgc 111  
Met Ala Asp Ser Ser Glu Gly Pro Arg  
1 5

gcg ggg ccc ggg gag gtg gct gag ctc ccc ggg gat gag agt ggc acc 159  
Ala Gly Pro Gly Glu Val Ala Glu Leu Pro Gly Asp Glu Ser Gly Thr  
10 15 20 25

cca ggt ggg gag gct ttt cct ctc tcc tcc ctg gcc aat ctg ttt gag 207  
Pro Gly Gly Glu Ala Phe Pro Leu Ser Ser Leu Ala Asn Leu Phe Glu  
30 35 40

ggg gag gat ggc tcc ctt tcg ccc tca ccg gct gat gcc agt cgc cct 255  
Gly Glu Asp Gly Ser Leu Ser Pro Ser Pro Ala Asp Ala Ser Arg Pro  
45 50 55

gct ggc cca ggc gat ggg cga cca aat ctg cgc atg aag ttc cag ggc 303  
Ala Gly Pro Gly Asp Gly Arg Pro Asn Leu Arg Met Lys Phe Gln Gly  
60 65 70

gcc ttc cgc aag ggg gtg ccc aac ccc atc gat ctg ctg gag tcc acc 351  
Ala Phe Arg Lys Gly Val Pro Asn Pro Ile Asp Leu Leu Glu Ser Thr  
75 80 85

cta tat gag tcc tcg gtg gtg cct ggg ccc aag aaa gca ccc atg gac 399  
Leu Tyr Glu Ser Ser Val Val Pro Gly Pro Lys Lys Ala Pro Met Asp  
90 95 100 105

tca ctg ttt gac tac ggc acc tat cgt cac cac tcc agt gac aac aag 447  
Ser Leu Phe Asp Tyr Gly Thr Tyr Arg His His Ser Ser Asp Asn Lys  
110 115 120

EP 1 160 254 A1

	agg	tgg	agg	aag	aag	atc	ata	gag	aag	cag	ccg	cag	agc	ccc	aaa	gcc	495
	Arg	Trp	Arg	Lys	Lys	Ile	Ile	Glu	Lys	Gln	Pro	Gln	Ser	Pro	Lys	Ala	
				125					130					135			
5	cct	gcc	cct	cag	ccg	ccc	ccc	atc	ctc	aaa	gtc	ttc	aac	cgg	cct	atc	543
	Pro	Ala	Pro	Gln	Pro	Pro	Pro	Ile	Leu	Lys	Val	Phe	Asn	Arg	Pro	Ile	
			140					145				150					
10	ctc	ttt	gac	atc	gtg	tcc	cgg	ggc	tcc	act	gct	gac	ctg	gac	ggg	ctg	591
	Leu	Phe	Asp	Ile	Val	Ser	Arg	Gly	Ser	Thr	Ala	Asp	Leu	Asp	Gly	Leu	
		155					160					165					
	ctc	cca	ttc	ttg	ctg	acc	cac	aag	aaa	cgc	cta	act	gat	gag	gag	ttt	639
	Leu	Pro	Phe	Leu	Leu	Thr	His	Lys	Lys	Arg	Leu	Thr	Asp	Glu	Glu	Phe	
	170					175					180					185	
15	cga	gag	cca	tct	acg	ggg	aag	acc	tgc	ctg	ccc	aag	gcc	ttg	ctg	aac	687
	Arg	Glu	Pro	Ser	Thr	Gly	Lys	Thr	Cys	Leu	Pro	Lys	Ala	Leu	Leu	Asn	
					190				195					200			
20	ctg	agc	aat	ggc	cgc	aac	gac	acc	atc	cct	gtg	ctg	ctg	gac	atc	gcg	735
	Leu	Ser	Asn	Gly	Arg	Asn	Asp	Thr	Ile	Pro	Val	Leu	Leu	Asp	Ile	Ala	
			205					210						215			
	gag	cgc	acc	ggc	aac	atg	cgg	gag	ttc	att	aac	tcg	ccc	ttc	cgt	gac	783
	Glu	Arg	Thr	Gly	Asn	Met	Arg	Glu	Phe	Ile	Asn	Ser	Pro	Phe	Arg	Asp	
			220				225					230					
25	atc	tac	tat	cga	ggc	cag	aca	gcc	ctg	cac	atc	gcc	att	gag	cgt	cgc	831
	Ile	Tyr	Tyr	Arg	Gly	Gln	Thr	Ala	Leu	His	Ile	Ala	Ile	Glu	Arg	Arg	
		235				240						245					
30	tgc	aaa	cac	tac	gtg	gaa	ctt	ctc	gtg	gcc	cag	gga	gct	gat	gtc	cac	879
	Cys	Lys	His	Tyr	Val	Glu	Leu	Leu	Val	Ala	Gln	Gly	Ala	Asp	Val	His	
	250					255					260					265	
	gcc	cag	gcc	cgt	ggg	cgc	ttc	ttc	cag	ccc	aag	gat	gag	ggg	ggc	tac	927
	Ala	Gln	Ala	Arg	Gly	Arg	Phe	Phe	Gln	Pro	Lys	Asp	Glu	Gly	Gly	Tyr	
				270						275					280		
35	ttc	tac	ttt	ggg	gag	ctg	ccc	ctg	tcg	ctg	gct	gcc	tgc	acc	aac	cag	975
	Phe	Tyr	Phe	Gly	Glu	Leu	Pro	Leu	Ser	Leu	Ala	Ala	Cys	Thr	Asn	Gln	
			285					290					295				
40	ccc	cac	att	gtc	aac	tac	cta	acg	gag	aac	ccc	cac	aag	aag	gcg	gac	1023
	Pro	His	Ile	Val	Asn	Tyr	Leu	Thr	Glu	Asn	Pro	His	Lys	Lys	Ala	Asp	
			300					305					310				
45	atg	cgg	cgc	cag	gac	tcg	cga	ggc	aac	aca	gtg	ctg	cat	gcg	ctg	gtg	1071
	Met	Arg	Arg	Gln	Asp	Ser	Arg	Gly	Asn	Thr	Val	Leu	His	Ala	Leu	Val	
		315				320						325					
	gcc	att	gct	gac	aac	acc	cgt	gag	aac	acc	aag	ttt	gtt	acc	aag	atg	1119
	Ala	Ile	Ala	Asp	Asn	Thr	Arg	Glu	Asn	Thr	Lys	Phe	Val	Thr	Lys	Met	
	330					335					340					345	
50	tac	gac	ctg	ctg	ctg	ctc	aag	tgt	gcc	cgc	ctc	ttc	ccc	gac	agc	aac	1167
	Tyr	Asp	Leu	Leu	Leu	Leu	Lys	Cys	Ala	Arg	Leu	Phe	Pro	Asp	Ser	Asn	
					350					355					360		
	ctg	gag	gcc	gtg	ctc	aac	aac	gac	ggc	ctc	tcg	ccc	ctc	atg	atg	gct	1215
	Leu	Glu	Ala	Val	Leu	Asn	Asn	Asp	Gly	Leu	Ser	Pro	Leu	Met	Met	Ala	

55

EP 1 160 254 A1

	365							370					375					
5	gcc	aag	acg	ggc	aag	att	ggg	atc	ttt	cag	cac	atc	atc	cgg	cgg	gag	1263	
	Ala	Lys	Thr	Gly	Lys	Ile	Gly	Ile	Phe	Gln	His	Ile	Ile	Arg	Arg	Glu		
			380					385					390					
	gtg	acg	gat	gag	gac	aca	cgg	cac	ctg	tcc	cgc	aag	ttc	aag	gac	tgg	1311	
	Val	Thr	Asp	Glu	Asp	Thr	Arg	His	Leu	Ser	Arg	Lys	Phe	Lys	Asp	Trp		
			395				400					405						
10	gcc	tat	ggg	cca	gtg	tat	tcc	tgc	ctt	tat	gac	ctc	tcc	tcc	ctg	gac	1359	
	Ala	Tyr	Gly	Pro	Val	Tyr	Ser	Ser	Leu	Tyr	Asp	Leu	Ser	Ser	Leu	Asp		
	410					415					420				425			
15	acg	tgt	ggg	gaa	gag	gcc	tcc	gtg	ctg	gag	atc	ctg	gtg	tac	aac	agc	1407	
	Thr	Cys	Gly	Glu	Glu	Ala	Ser	Val	Leu	Glu	Ile	Leu	Val	Tyr	Asn	Ser		
					430					435					440			
	aag	att	gag	aac	cgc	cac	gag	atg	ctg	gct	gtg	gag	ccc	atc	aat	gaa	1455	
	Lys	Ile	Glu	Asn	Arg	His	Glu	Met	Leu	Ala	Val	Glu	Pro	Ile	Asn	Glu		
				445					450					455				
20	ctg	ctg	cgg	gac	aag	tgg	cgc	aag	ttc	ggg	gcc	gtc	tcc	ttc	tac	atc	1503	
	Leu	Leu	Arg	Asp	Lys	Trp	Arg	Lys	Phe	Gly	Ala	Val		Phe	Tyr	Ile		
			460					465					470					
25	aac	gtg	gtc	tcc	tac	ctg	tgt	gcc	atg	gtc	atc	ttc	act	ctc	acc	gcc	1551	
	Asn	Val	Val	Ser	Tyr	Leu	Cys	Ala	Met	Val	Ile	Phe	Thr	Leu	Thr	Ala		
		475					480					485						
	tac	tac	cag	ccg	ctg	gag	ggc	aca	ccg	ccg	tac	cct	tac	cgc	acc	acg	1599	
	Tyr	Tyr	Gln	Pro	Leu	Glu	Gly	Thr	Pro	Pro	Tyr	Pro	Tyr	Arg	Thr	Thr		
	490					495					500					505		
30	gtg	gac	tac	ctg	cgg	ctg	gct	ggc	gag	gtc	att	acg	ctc	ttc	act	ggg	1647	
	Val	Asp	Tyr	Leu	Arg	Leu	Ala	Gly	Glu	Val	Ile	Thr	Leu	Phe	Thr	Gly		
					510					515					520			
35	gtc	ctg	ttc	ttc	ttc	acc	aac	atc	aaa	gac	ttg	ttc	atg	aag	aaa	tgc	1695	
	Val	Leu	Phe	Phe	Phe	Thr	Asn	Ile	Lys	Asp	Leu	Phe	Met	Lys	Lys	Cys		
				525					530					535				
	cct	gga	gtg	aat	tct	ctc	ttc	att	gat	ggc	tcc	ttc	cag	ctg	ctc	tac	1743	
	Pro	Gly	Val	Asn	Ser	Leu	Phe	Ile	Asp	Gly	Ser	Phe	Gln	Leu	Leu	Tyr		
			540					545					550					
40	ttc	atc	tac	tct	gtc	ctg	gtg	atc	gtc	tca	gca	gcc	ctc	tac	ctg	gca	1791	
	Phe	Ile	Tyr	Ser	Val	Leu	Val	Ile	Val	Ser	Ala	Ala	Leu	Tyr	Leu	Ala		
		555					560					565						
45	ggg	atc	gag	gcc	tac	ctg	gcc	gtg	atg	gtc	ttt	gcc	ctg	gtc	ctg	ggc	1839	
	Gly	Ile	Glu	Ala	Tyr	Leu	Ala	Val	Met	Val	Phe	Ala	Leu	Val	Leu	Gly		
	570					575					580				585			
	tgg	atg	aat	gcc	ctt	tac	ttc	acc	cgt	ggg	ctg	aag	ctg	acg	ggg	acc	1887	
	Trp	Met	Asn	Ala	Leu	Tyr	Phe	Thr	Arg	Gly	Leu	Lys	Leu	Thr	Gly	Thr		
					590					595					600			
50	tat	agc	atc	atg	atc	cag	aag	att	ctc	ttc	aag	gac	ctt	ttc	cga	ttc	1935	
	Tyr	Ser	Ile	Met	Ile	Gln	Lys	Ile	Leu	Phe	Lys	Asp	Leu	Phe	Arg	Phe		
				605					610					615				
55	ctg	ctc	gtc	tac	ttg	ctc	ttc	atg	atc	ggc	tac	gct	tca	gcc	ctg	gtc	1983	

EP 1 160 254 A1

	Leu	Leu	Val	Tyr	Leu	Leu	Phe	Met	Ile	Gly	Tyr	Ala	Ser	Ala	Leu	Val	
			620					625					630				
5	tcc	ctc	ctg	aac	ccg	tgt	gcc	aac	atg	aag	gtg	tgc	aat	gag	gac	cag	2031
	Ser	Leu	Leu	Asn	Pro	Cys	Ala	Asn	Met	Lys	Val	Cys	Asn	Glu	Asp	Gln	
		635					640					645					
10	acc	aac	tgc	aca	gtg	ccc	act	tac	ccc	tgc	tgc	cgt	gac	agc	gag	acc	2079
	Thr	Asn	Cys	Thr	Val	Pro	Thr	Tyr	Pro	Ser	Cys	Arg	Asp	Ser	Glu	Thr	
	650					655					660					665	
15	ttc	agc	acc	ttc	ctc	ctg	gac	ctg	ttt	aag	ctg	acc	att	ggc	atg	ggc	2127
	Phe	Ser	Thr	Phe	Leu	Leu	Asp	Leu	Phe	Lys	Leu	Thr	Ile	Gly	Met	Gly	
				670						675					680		
20	gac	ctg	gag	atg	ctg	agc	agc	acc	aag	tac	ccc	gtg	gtc	ttc	atc	atc	2175
	Asp	Leu	Glu	Met	Leu	Ser	Ser	Thr	Lys	Tyr	Pro	Val	Val	Phe	Ile	Ile	
				685					690					695			
25	ctg	ctg	gtg	acc	tac	atc	atc	ctc	acc	ttt	gtg	ctg	ctc	ctc	aac	atg	2223
	Leu	Leu	Val	Thr	Tyr	Ile	Ile	Leu	Thr	Phe	Val	Leu	Leu	Leu	Asn	Met	
			700					705					710				
30	ctc	att	gcc	ctc	atg	ggc	gag	aca	gtg	ggc	cag	gtc	tcc	aag	gag	agc	2271
	Leu	Ile	Ala	Leu	Met	Gly	Glu	Thr	Val	Gly	Gln	Val	Ser	Lys	Glu	Ser	
		715					720					725					
35	aag	cac	atc	tgg	aag	ctg	cag	tgg	gcc	acc	acc	atc	ctg	gac	att	gag	2319
	Lys	His	Ile	Trp	Lys	Leu	Gln	Trp	Ala	Thr	Thr	Ile	Leu	Asp	Ile	Glu	
	730					735					740					745	
40	cgc	tcc	ttc	ccc	gta	ttc	ctg	agg	aag	gcc	ttc	cgc	tct	ggg	gag	atg	2367
	Arg	Ser	Phe	Pro	Val	Phe	Leu	Arg	Lys	Ala	Phe	Arg	Ser	Gly	Glu	Met	
				750						755					760		
45	gtc	acc	gtg	ggc	aag	agc	tgc	gac	ggc	act	cct	gac	cgc	agg	tgg	tgc	2415
	Val	Thr	Val	Gly	Lys	Ser	Ser	Asp	Gly	Thr	Pro	Asp	Arg	Arg	Trp	Cys	
				765					770					775			
50	ttc	agg	gtg	gat	gag	gtg	aac	tgg	tct	cac	tgg	aac	cag	aac	ttg	ggc	2463
	Phe	Arg	Val	Asp	Glu	Val	Asn	Trp	Ser	His	Trp	Asn	Gln	Asn	Leu	Gly	
			780					785					790				
55	atc	atc	aac	gag	gac	ccg	ggc	aag	aat	gag	acc	tac	cag	tat	tat	ggc	2511
	Ile	Ile	Asn	Glu	Asp	Pro	Gly	Lys	Asn	Glu	Thr	Tyr	Gln	Tyr	Tyr	Gly	
		795					800					805					
60	ttc	tgc	cat	acc	gtg	ggc	cgc	ctc	cgc	agg	gat	cgc	tgg	tcc	tgc	gtg	2559
	Phe	Ser	His	Thr	Val	Gly	Arg	Leu	Arg	Arg	Asp	Arg	Trp	Ser	Ser	Val	
	810					815					820					825	
65	gta	ccc	cgc	gtg	gtg	gaa	ctg	aac	aag	aac	tgc	aac	ccg	gac	gag	gtg	2607
	Val	Pro	Arg	Val	Val	Glu	Leu	Asn	Lys	Asn	Ser	Asn	Pro	Asp	Glu	Val	
					830					835					840		
70	gtg	gtg	cct	ctg	gac	agc	atg	ggg	aac	ccc	cgc	tgc	gat	ggc	cac	cag	2655
	Val	Val	Pro	Leu	Asp	Ser	Met	Gly	Asn	Pro	Arg	Cys	Asp	Gly	His	Gln	
				845				850						855			
75	cag	ggt	tac	ccc	cgc	aag	tgg	agg	act	gat	gac	gcc	ccg	ctc	tag		2700
	Gln	Gly	Tyr	Pro	Arg	Lys	Trp	Arg	Thr	Asp	Asp	Ala	Pro	Leu			
			860					865					870				



ggactgcagc ccagccccag cttctctgcc cactcatttc tagtccagc

2749

5 <210> 2  
 <211> 871  
 <212> PRT  
 <213> Human

10 <400> 2  
 Met Ala Asp Ser Ser Glu Gly Pro Arg Ala Gly Pro Gly Glu Val Ala  
 1 5 10 15  
 Glu Leu Pro Gly Asp Glu Ser Gly Thr Pro Gly Gly Glu Ala Phe Pro  
 20 25 30  
 Leu Ser Ser Leu Ala Asn Leu Phe Glu Gly Glu Asp Gly Ser Leu Ser  
 35 40 45  
 15 Pro Ser Pro Ala Asp Ala Ser Arg Pro Ala Gly Pro Gly Asp Gly Arg  
 50 55 60  
 Pro Asn Leu Arg Met Lys Phe Gln Gly Ala Phe Arg Lys Gly Val Pro  
 65 70 75 80  
 Asn Pro Ile Asp Leu Leu Glu Ser Thr Leu Tyr Glu Ser Ser Val Val  
 85 90 95  
 20 Pro Gly Pro Lys Lys Ala Pro Met Asp Ser Leu Phe Asp Tyr Gly Thr  
 100 105 110  
 Tyr Arg His His Ser Ser Asp Asn Lys Arg Trp Arg Lys Lys Ile Ile  
 115 120 125  
 25 Glu Lys Gln Pro Gln Ser Pro Lys Ala Pro Ala Pro Gln Pro Pro Pro  
 130 135 140  
 Ile Leu Lys Val Phe Asn Arg Pro Ile Leu Phe Asp Ile Val Ser Arg  
 145 150 155 160  
 Gly Ser Thr Ala Asp Leu Asp Gly Leu Leu Pro Phe Leu Leu Thr His  
 165 170 175  
 30 Lys Lys Arg Leu Thr Asp Glu Glu Phe Arg Glu Pro Ser Thr Gly Lys  
 180 185 190  
 Thr Cys Leu Pro Lys Ala Leu Leu Asn Leu Ser Asn Gly Arg Asn Asp  
 195 200 205  
 Thr Ile Pro Val Leu Leu Asp Ile Ala Glu Arg Thr Gly Asn Met Arg  
 210 215 220  
 35 Glu Phe Ile Asn Ser Pro Phe Arg Asp Ile Tyr Tyr Arg Gly Gln Thr  
 225 230 235 240  
 Ala Leu His Ile Ala Ile Glu Arg Arg Cys Lys His Tyr Val Glu Leu  
 245 250 255  
 Leu Val Ala Gln Gly Ala Asp Val His Ala Gln Ala Arg Gly Arg Phe  
 260 265 270  
 40 Phe Gln Pro Lys Asp Glu Gly Gly Tyr Phe Tyr Phe Gly Glu Leu Pro  
 275 280 285  
 Leu Ser Leu Ala Ala Cys Thr Asn Gln Pro His Ile Val Asn Tyr Leu  
 290 295 300  
 Thr Glu Asn Pro His Lys Lys Ala Asp Met Arg Arg Gln Asp Ser Arg  
 305 310 315 320  
 45 Gly Asn Thr Val Leu His Ala Leu Val Ala Ile Ala Asp Asn Thr Arg  
 325 330 335  
 Glu Asn Thr Lys Phe Val Thr Lys Met Tyr Asp Leu Leu Leu Leu Lys  
 340 345 350  
 Cys Ala Arg Leu Phe Pro Asp Ser Asn Leu Glu Ala Val Leu Asn Asn  
 355 360 365  
 50 Asp Gly Leu Ser Pro Leu Met Met Ala Ala Lys Thr Gly Lys Ile Gly  
 370 375 380  
 Ile Phe Gln His Ile Ile Arg Arg Glu Val Thr Asp Glu Asp Thr Arg  
 385 390 395 400  
 His Leu Ser Arg Lys Phe Lys Asp Trp Ala Tyr Gly Pro Val Tyr Ser  
 405 410 415  
 55 Ser Leu Tyr Asp Leu Ser Ser Leu Asp Thr Cys Gly Glu Glu Ala Ser  
 420 425 430

EP 1 160 254 A1

	Val	Leu	Glu	Ile	Leu	Val	Tyr	Asn	Ser	Lys	Ile	Glu	Asn	Arg	His	Glu
			435					440					445			
5	Met	Leu	Ala	Val	Glu	Pro	Ile	Asn	Glu	Leu	Leu	Arg	Asp	Lys	Trp	Arg
		450					455					460				
	Lys	Phe	Gly	Ala	Val	Ser	Phe	Tyr	Ile	Asn	Val	Val	Ser	Tyr	Leu	Cys
	465					470					475				480	
	Ala	Met	Val	Ile	Phe	Thr	Leu	Thr	Ala	Tyr	Tyr	Gln	Pro	Leu	Glu	Gly
					485					490					495	
10	Thr	Pro	Pro	Tyr	Pro	Tyr	Arg	Thr	Thr	Val	Asp	Tyr	Leu	Arg	Leu	Ala
				500					505					510		
	Gly	Glu	Val	Ile	Thr	Leu	Phe	Thr	Gly	Val	Leu	Phe	Phe	Phe	Thr	Asn
			515					520					525			
	Ile	Lys	Asp	Leu	Phe	Met	Lys	Lys	Cys	Pro	Gly	Val	Asn	Ser	Leu	Phe
		530					535					540				
15	Ile	Asp	Gly	Ser	Phe	Gln	Leu	Leu	Tyr	Phe	Ile	Tyr	Ser	Val	Leu	Val
	545					550					555				560	
	Ile	Val	Ser	Ala	Ala	Leu	Tyr	Leu	Ala	Gly	Ile	Glu	Ala	Tyr	Leu	Ala
					565					570					575	
	Val	Met	Val	Phe	Ala	Leu	Val	Leu	Gly	Trp	Met	Asn	Ala	Leu	Tyr	Phe
				580					585					590		
20	Thr	Arg	Gly	Leu	Lys	Leu	Thr	Gly	Thr	Tyr	Ser	Ile	Met	Ile	Gln	Lys
			595					600					605			
	Ile	Leu	Phe	Lys	Asp	Leu	Phe	Arg	Phe	Leu	Leu	Val	Tyr	Leu	Leu	Phe
		610					615					620				
	Met	Ile	Gly	Tyr	Ala	Ser	Ala	Leu	Val	Ser	Leu	Leu	Asn	Pro	Cys	Ala
	625					630					635				640	
25	Asn	Met	Lys	Val	Cys	Asn	Glu	Asp	Gln	Thr	Asn	Cys	Thr	Val	Pro	Thr
					645					650					655	
	Tyr	Pro	Ser	Cys	Arg	Asp	Ser	Glu	Thr	Phe	Ser	Thr	Phe	Leu	Leu	Asp
				660					665					670		
	Leu	Phe	Lys	Leu	Thr	Ile	Gly	Met	Gly	Asp	Leu	Glu	Met	Leu	Ser	Ser
			675					680					685			
30	Thr	Lys	Tyr	Pro	Val	Val	Phe	Ile	Ile	Leu	Leu	Val	Thr	Tyr	Ile	Ile
		690					695					700				
	Leu	Thr	Phe	Val	Leu	Leu	Asn	Met	Leu	Ile	Ala	Leu	Met	Gly	Glu	
					710					715					720	
	Thr	Val	Gly	Gln	Val	Ser	Lys	Glu	Ser	Lys	His	Ile	Trp	Lys	Leu	Gln
					725					730					735	
35	Trp	Ala	Thr	Thr	Ile	Leu	Asp	Ile	Glu	Arg	Ser	Phe	Pro	Val	Phe	Leu
				740					745					750		
	Arg	Lys	Ala	Phe	Arg	Ser	Gly	Glu	Met	Val	Thr	Val	Gly	Lys	Ser	Ser
			755					760					765			
	Asp	Gly	Thr	Pro	Asp	Arg	Arg	Trp	Cys	Phe	Arg	Val	Asp	Glu	Val	Asn
		770					775					780				
40	Trp	Ser	His	Trp	Asn	Gln	Asn	Leu	Gly	Ile	Ile	Asn	Glu	Asp	Pro	Gly
					790						795					800
	Lys	Asn	Glu	Thr	Tyr	Gln	Tyr	Tyr	Gly	Phe	Ser	His	Thr	Val	Gly	Arg
					805					810					815	
	Leu	Arg	Arg	Asp	Arg	Trp	Ser	Ser	Val	Val	Pro	Arg	Val	Val	Glu	Leu
				820					825					830		
45	Asn	Lys	Asn	Ser	Asn	Pro	Asp	Glu	Val	Val	Val	Pro	Leu	Asp	Ser	Met
			835					840					845			
	Gly	Asn	Pro	Arg	Cys	Asp	Gly	His	Gln	Gln	Gly	Tyr	Pro	Arg	Lys	Trp
		850					855					860				
	Arg	Thr	Asp	Asp	Ala	Pro	Leu									
	865					870										

50

<210> 3  
 <211> 1900  
 <212> DNA  
 <213> Human

55

EP 1 160 254 A1

<220>  
<221> CDS  
<222> (43)..(1851)

5	<400> 3	
	gcggccgctg aattctagga catcgcgagg cgcaccggca ac atg cgg gag ttc	54
	Met Arg Glu Phe	
	1	
10	att aac tcg ccc ttc cgt gac atc tac tat cga ggg gag ctg ccc ctg	102
	Ile Asn Ser Pro Phe Arg Asp Ile Tyr Tyr Arg Gly Glu Leu Pro Leu	
	5 10 15 20	
	tcg ctg gct gcc tgc acc aac cag ccc cac att gtc aac tac ctg acg	150
	Ser Leu Ala Ala Cys Thr Asn Gln Pro His Ile Val Asn Tyr Leu Thr	
15	25 30	
	gag aac ccc cac aag aag gcg gac atg cgg cgc cag gac tcg cga ggc	198
	Glu Asn Pro His Lys Lys Ala Asp Met Arg Arg Gln Asp Ser Arg Gly	
	40 45 50	
20	aac aca gtg ctg cat gcg ctg gtg gcc att gct gac aac acc cgt gag	246
	Asn Thr Val Leu His Ala Leu Val Ala Ile Ala Asp Asn Thr Arg Glu	
	55 60 65	
	aac acc aag ttt gtt acc aag atg tac gac ctg ctg ctg ctc aag tgt	294
	Asn Thr Lys Phe Val Thr Lys Met Tyr Asp Leu Leu Leu Lys Cys	
25	70 75 80	
	gcc cgc ctc ttc ccc gac agc aac ctg gag gcc gtg ctc aac aac gac	342
	Ala Arg Leu Phe Pro Asp Ser Asn Leu Glu Ala Val Leu Asn Asn Asp	
	85 90 95 100	
30	ggc ctc tcg ccc ctc atg atg gct gcc aag acg ggc aag att ggg atc	390
	Gly Leu Ser Pro Leu Met Met Ala Ala Lys Thr Gly Lys Ile Gly Ile	
	105 110 115	
	ttt cag cac atc atc cgg cgg gag gtg acg gat gag gac aca cgg cac	438
	Phe Gln His Ile Ile Arg Arg Glu Val Thr Asp Glu Asp Thr Arg His	
35	120 125 130	
	ctg tcc cgc aag ttc aag gac tgg gcc tat ggg cca gtg tat tcc tcg	486
	Leu Ser Arg Lys Phe Lys Asp Trp Ala Tyr Gly Pro Val Tyr Ser Ser	
	135 140 145	
40	ctt tat gac ctc tcc tcc ctg gac acg tgt ggg gaa gag gcc tcc gtg	534
	Leu Tyr Asp Leu Ser Ser Leu Asp Thr Cys Gly Glu Glu Ala Ser Val	
	150 155 160	
	ctg gag atc ctg gtg tac aac agc aag att gag aac cgc cac gag atg	582
	Leu Glu Ile Leu Val Tyr Asn Ser Lys Ile Glu Asn Arg His Glu Met	
45	165 170 175 180	
	ctg gct gtg gag ccc atc aat gaa ctg ctg cgg gac aag tgg cgc aag	630
	Leu Ala Val Glu Pro Ile Asn Glu Leu Leu Arg Asp Lys Trp Arg Lys	
	185 190 195	
50	ttc ggg gcc gtc tcc ttc tac atc aac gtg gtc tcc tac ctg tgt gcc	678
	Phe Gly Ala Val Ser Phe Tyr Ile Asn Val Val Ser Tyr Leu Cys Ala	
	200 205 210	
	atg gtc atc ttc act ctc acc gcc tac tac cag ccg ctg gag ggc aca	726
55		

EP 1 160 254 A1

	Met	Val	Ile	Phe	Thr	Leu	Thr	Ala	Tyr	Tyr	Gln	Pro	Leu	Glu	Gly	Thr	
			215					220					225				
5	cgc	ccg	tac	cct	tac	cgc	acc	acg	gtg	gac	tac	ctg	cgg	ctg	gct	ggc	774
	Pro	Pro	Tyr	Pro	Tyr	Arg	Thr	Thr	Val	Asp	Tyr	Leu	Arg	Leu	Ala	Gly	
		230					235					240					
10	gag	gtc	att	acg	ctc	ttc	act	ggg	gtc	ctg	ttc	ttc	ttc	acc	aac	atc	822
	Glu	Val	Ile	Thr	Leu	Phe	Thr	Gly	Val	Leu	Phe	Phe	Phe	Thr	Asn	Ile	
	245					250					255					260	
15	aaa	gac	ttg	ttc	atg	aag	aaa	tgc	cct	gga	gtg	aat	tct	ctc	ttc	att	870
	Lys	Asp	Leu	Phe	Met	Lys	Lys	Cys	Pro	Gly	Val	Asn	Ser	Leu	Phe	Ile	
					265					270					275		
20	gat	ggc	tcc	ttc	cag	ctg	ctc	tac	ttc	atc	tac	tct	gtc	ctg	gtg	atc	918
	Asp	Gly	Ser	Phe	Gln	Leu	Leu	Tyr	Phe	Ile	Tyr	Ser	Val	Leu	Val	Ile	
				280					285					290			
25	gtc	tca	gca	gcc	ctc	tac	ctg	gca	ggg	atc	gag	gcc	tac	ctg	gcc	gtg	966
	Val	Ser	Ala	Ala	Leu	Tyr	Leu	Ala	Gly	Ile	Glu	Ala	Tyr	Leu	Ala	Val	
			295					300				305					
30	atg	gtc	ttt	gcc	ctg	gtc	ctg	ggc	tgg	atg	aat	gcc	ctt	tac	ttc	acc	1014
	Met	Val	Phe	Ala	Leu	Val	Leu	Gly	Trp	Met	Asn	Ala	Leu	Tyr	Phe	Thr	
		310					315					320					
35	cgt	ggg	ctg	aag	ctg	acg	ggg	acc	tat	agc	atc	atg	atc	cag	aag	att	1062
	Arg	Gly	Leu	Lys	Leu	Thr	Gly	Thr	Tyr	Ser	Ile	Met	Ile	Gln	Lys	Ile	
	325					330					335					340	
40	ctc	ttc	aag	gac	ctt	ttc	cga	ttc	ctg	ctc	gtc	tac	ttg	ctc	ttc	atg	1110
	Leu	Phe	Lys	Asp	Leu	Phe	Arg	Phe	Leu	Leu	Val	Tyr	Leu	Leu	Phe	Met	
					345				350						355		
45	atc	ggc	tac	gct	tca	gcc	ctg	gtc	tcc	ctc	ctg	aac	ccg	tgt	gcc	aac	1158
	Ile	Gly	Tyr	Ala	Ser	Ala	Leu	Val	Ser	Leu	Leu	Asn	Pro	Cys	Ala	Asn	
				360					365					370			
50	atg	aag	gtg	tgc	aat	gag	gac	cag	acc	aac	tgc	aca	gtg	ccc	act	tac	1206
	Met	Lys	Val	Cys	Asn	Glu	Asp	Gln	Thr	Asn	Cys	Thr	Val	Pro	Thr	Tyr	
			375					380					385				
55	ccc	tgc	tgc	cgt	gac	agc	gag	acc	ttc	agc	acc	ttc	ctc	ctg	gac	ctg	1254
	Pro	Ser	Cys	Arg	Asp	Ser	Glu	Thr	Phe	Ser	Thr	Phe	Leu	Leu	Asp	Leu	
			390				395					400					
60	ttt	aag	ctg	acc	atc	ggc	atg	ggc	gac	ctg	gag	atg	ctg	agc	agc	acc	1302
	Phe	Lys	Leu	Thr	Ile	Gly	Met	Gly	Asp	Leu	Glu	Met	Leu	Ser	Ser	Thr	
	405					410					415					420	
65	aag	tac	ccc	gtg	gtc	ttc	atc	atc	ctg	ctg	gtg	acc	tac	atc	atc	ctc	1350
	Lys	Tyr	Pro	Val	Val	Phe	Ile	Ile	Leu	Leu	Val	Thr	Tyr	Ile	Ile	Leu	
					425				430					435			
70	acc	ttt	gtg	ctg	ctc	ctc	aac	atg	ctc	att	gcc	ctc	atg	ggc	gag	aca	1398
	Thr	Phe	Val	Leu	Leu	Leu	Asn	Met	Leu	Ile	Ala	Leu	Met	Gly	Glu	Thr	
				440				445					450				
75	gtg	ggc	cag	gtc	tcc	aag	gag	agc	aag	cac	atc	tgg	aag	ctg	cag	tgg	1446
	Val	Gly	Gln	Val	Ser	Lys	Glu	Ser	Lys	His	Ile	Trp	Lys	Leu	Gln	Trp	
			455					460					465				

EP 1 160 254 A1

5 gcc acc acc atc ctg gac att gag cgc tcc ttc ccc gta ttc ctg agg 1494  
Ala Thr Thr Ile Leu Asp Ile Glu Arg Ser Phe Pro Val Phe Leu Arg  
470 475 480

aag gcc ttc cgc tct ggg gag atg gtc acc gtg ggc aag agc tcg gac 1542  
Lys Ala Phe Arg Ser Gly Glu Met Val Thr Val Gly Lys Ser Ser Asp  
485 490 495 500

10 ggc act cct gac cgc agg tgg tgc ttc agg gtg gat gag gtg aac tgg 1590  
Gly Thr Pro Asp Arg Arg Trp Cys Phe Arg Val Asp Glu Val Asn Trp  
505 510 515

15 tct cac tgg aac cag aac ttg ggc atc atc aac gag gac ccg ggc aag 1638  
Ser His Trp Asn Gln Asn Leu Gly Ile Ile Asn Glu Asp Pro Gly Lys  
520 525 530

aat gag acc tac cag tat tat ggc ttc tcg cat acc gtg ggc cgc ctc 1686  
Asn Glu Thr Tyr Gln Tyr Tyr Gly Phe Ser His Thr Val Gly Arg Leu  
535 540 545

20 cgc agg gat cgc tgg tcc tcg gtg gta ccc cgc gtg gtg gaa ctg aac 1734  
Arg Arg Asp Arg Trp Ser Ser Val Val Pro Arg Val Val Glu Leu Asn  
550 555 560

25 aag aac tcg aac ccg gac gag gtg gtg gtg cct ctg gac agc atg ggg 1782  
Lys Asn Ser Asn Pro Asp Glu Val Val Val Pro Leu Asp Ser Met Gly  
565 570 575 580

aac ccc cgc tgc gat ggc cac cag cag ggt tac ccc cgc aag tgg agg 1830  
Asn Pro Arg Cys Asp Gly His Gln Gln Gly Tyr Pro Arg Lys Trp Arg  
585 590 595

30 act gat gac gcc ccg ctc tag ggactgcagc ccagccccag cttctctgcc 1881  
Thr Asp Asp Ala Pro Leu  
600

cactcatttc tagtccagc 1900

35 <210> 4  
<211> 602  
<212> PRT  
<213> Human

40 <400> 4  
Met Arg Glu Phe Ile Asn Ser Pro Phe Arg Asp Ile Tyr Tyr Arg Gly  
1 5 10 15  
Glu Leu Pro Leu Ser Leu Ala Ala Cys Thr Asn Gln Pro His Ile Val  
20 25 30  
Asn Tyr Leu Thr Glu Asn Pro His Lys Lys Ala Asp Met Arg Arg Gln  
35 40 45  
Asp Ser Arg Gly Asn Thr Val Leu His Ala Leu Val Ala Ile Ala Asp  
50 55 60  
Asn Thr Arg Glu Asn Thr Lys Phe Val Thr Lys Met Tyr Asp Leu Leu  
65 70 75 80  
Leu Leu Lys Cys Ala Arg Leu Phe Pro Asp Ser Asn Leu Glu Ala Val  
85 90 95  
Leu Asn Asn Asp Gly Leu Ser Pro Leu Met Met Ala Ala Lys Thr Gly  
100 105 110  
Lys Ile Gly Ile Phe Gln His Ile Ile Arg Arg Glu Val Thr Asp Glu  
115 120 125  
Asp Thr Arg His Leu Ser Arg Lys Phe Lys Asp Trp Ala Tyr Gly Pro  
130 135 140

# EP 1 160 254 A1

	Val	Tyr	Ser	Ser	Leu	Tyr	Asp	Leu	Ser	Ser	Leu	Asp	Thr	Cys	Gly	Glu
	145					150					155					160
	Glu	Ala	Ser	Val	Leu	Glu	Ile	Leu	Val	Tyr	Asn	Ser	Lys	Ile	Glu	Asn
					165					170					175	
5	Arg	His	Glu	Met	Leu	Ala	Val	Glu	Pro	Ile	Asn	Glu	Leu	Leu	Arg	Asp
				180					185					190		
	Lys	Trp	Arg	Lys	Phe	Gly	Ala	Val	Ser	Phe	Tyr	Ile	Asn	Val	Val	Ser
			195					200					205			
	Tyr	Leu	Cys	Ala	Met	Val	Ile	Phe	Thr	Leu	Thr	Ala	Tyr	Tyr	Gln	Pro
		210					215					220				
10	Leu	Glu	Gly	Thr	Pro	Pro	Tyr	Pro	Tyr	Arg	Thr	Thr	Val	Asp	Tyr	Leu
	225					230					235					240
	Arg	Leu	Ala	Gly	Glu	Val	Ile	Thr	Leu	Phe	Thr	Gly	Val	Leu	Phe	Phe
					245					250					255	
	Phe	Thr	Asn	Ile	Lys	Asp	Leu	Phe	Met	Lys	Lys	Cys	Pro	Gly	Val	Asn
				260					265					270		
15	Ser	Leu	Phe	Ile	Asp	Gly	Ser	Phe	Gln	Leu	Leu	Tyr	Phe	Ile	Tyr	Ser
			275					280					285			
	Val	Leu	Val	Ile	Val	Ser	Ala	Ala	Leu	Tyr	Leu	Ala	Gly	Ile	Glu	Ala
		290					295					300				
	Tyr	Leu	Ala	Val	Met	Val	Phe	Ala	Leu	Val	Leu	Gly	Trp	Met	Asn	Ala
	305					310					315					320
20	Leu	Tyr	Phe	Thr	Arg	Gly	Leu	Lys	Leu	Thr	Gly	Thr	Tyr	Ser	Ile	Met
					325					330					335	
	Ile	Gln	Lys	Ile	Leu	Phe	Lys	Asp	Leu	Phe	Arg	Phe	Leu	Leu	Val	Tyr
				340					345					350		
	Leu	Leu	Phe	Met	Ile	Gly	Tyr	Ala	Ser	Ala	Leu	Val	Ser	Leu	Leu	Asn
			355					360					365			
25	Pro	Cys	Ala	Asn	Met	Lys	Val	Cys	Asn	Glu	Asp	Gln	Thr	Asn	Cys	Thr
		370					375					380				
	Val	Pro	Thr	Tyr	Pro	Ser	Cys	Arg	Asp	Ser	Glu	Thr	Phe	Ser	Thr	Phe
	385					390					395					400
	Leu	Leu	Asp	Leu	Phe	Lys	Leu	Thr	Ile	Gly	Met	Gly	Asp	Leu	Glu	Met
					405					410					415	
30	Leu	Ser	Ser	Thr	Lys	Tyr	Pro	Val	Val	Phe	Ile	Ile	Leu	Leu	Val	Thr
				420					425					430		
	Tyr	Ile	Ile	Leu	Thr	Phe	Val	Leu	Leu	Leu	Asn	Met	Leu	Ile	Ala	Leu
				435				440					445			
	Met	Gly	Glu	Thr	Val	Gly	Gln	Val	Ser	Lys	Glu	Ser	Lys	His	Ile	Trp
		450					455					460				
35	Lys	Leu	Gln	Trp	Ala	Thr	Thr	Ile	Leu	Asp	Ile	Glu	Arg	Ser	Phe	Pro
	465					470					475					480
	Val	Phe	Leu	Arg	Lys	Ala	Phe	Arg	Ser	Gly	Glu	Met	Val	Thr	Val	Gly
					485					490					495	
	Lys	Ser	Ser	Asp	Gly	Thr	Pro	Asp	Arg	Arg	Trp	Cys	Phe	Arg	Val	Asp
				500					505					510		
40	Glu	Val	Asn	Trp	Ser	His	Trp	Asn	Gln	Asn	Leu	Gly	Ile	Ile	Asn	Glu
			515					520					525			
	Asp	Pro	Gly	Lys	Asn	Glu	Thr	Tyr	Gln	Tyr	Tyr	Gly	Phe	Ser	His	Thr
		530					535					540				
	Val	Gly	Arg	Leu	Arg	Arg	Asp	Arg	Trp	Ser	Ser	Val	Val	Pro	Arg	Val
	545					550					555					560
45	Val	Glu	Leu	Asn	Lys	Asn	Ser	Asn	Pro	Asp	Glu	Val	Val	Val	Pro	Leu
					565					570					575	
	Asp	Ser	Met	Gly	Asn	Pro	Arg	Cys	Asp	Gly	His	Gln	Gln	Gly	Tyr	Pro
				580					585					590		
50	Arg	Lys	Trp	Arg	Thr	Asp	Asp	Ala	Pro	Leu						
			595					600								

## Claims

1. A polypeptide selected from:

- (a) a polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4, or variants thereof; and
- (b) a polypeptide having the deduced amino acid sequence translated from the polynucleotide sequence SEQ

ID NO:1 or SEQ ID NO:3, or variants thereof.

2. A polypeptide of Claim 1, comprising an amino acid sequence that has at least 75% identity to the an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
3. A polypeptide of Claim, comprising an amino acid sequence that has at least 85% identity to the an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
4. A polypeptide of Claim 1, comprising an amino acid sequence that has at least 95% identity to the an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4.
5. An isolated and/or purified polynucleotide selected from:
  - (a) a polynucleotide encoding the polypeptide comprising an amino acid sequence of SEQ ID NO:2 or SEQ ID NO:4;
  - (b) a polynucleotide having a nucleotide sequence of the 85th to 2700th nucleotides in the nucleotide sequence of SEQ ID NO:1, or a nucleotide sequence of the 43rd to 1851st nucleotides in the nucleotide sequence of SEQ ID NO:3 or variants thereof;
  - (c) a polynucleotide comprising a nucleotide sequence that has at least 70% identity to the polynucleotide of (a) or (b);
  - (d) a complement to the polynucleotide of any one of (a) to (c);
  - (e) a polynucleotide comprising a nucleotide sequence which is capable of hybridising to the polynucleotide of any one of (a) to (d); and
  - (f) a polynucleotide fragment of the polynucleotide of any one of (a) to (e).
6. A polynucleotide of claim 5, comprising a nucleotide sequence that has at least 75% identity to the nucleotide sequence of the polynucleotide (b).
7. A polynucleotide of claim 5, comprising a nucleotide sequence that has at least 85% identity to the nucleotide sequence of the polynucleotide (b).
8. A polynucleotide of claim 5, comprising a nucleotide sequence that has at least 95% identity to the nucleotide sequence of the polynucleotide (b).
9. A polynucleotide probe or primer comprising at least 15 contiguous nucleotides of the polynucleotide of any one of Claim 5.
10. An expression vector for the expression of a human vanilloid receptor-like protein in a recombinant host cell wherein said expression vector contains the polynucleotide of Claim 5.
11. A host cell which expresses a human vanilloid receptor-like protein wherein said host cell contains the expression vector of Claim 10.
12. A process for producing a polypeptide of Claim 1, which comprises culturing a host cell of Claim 11 under conditions sufficient for the production of said polypeptide and recovering the polypeptide from the culture medium.
13. An antibody immunospecific for a polypeptide of Claim 1.
14. A diagnostic kit for diagnosing a disease or a susceptibility to a disease associated with biological function of a human vanilloid receptor-like protein, which comprises a polynucleotide of Claim 5, or an antibody to a polypeptide of Claim 1.
15. A method for screening to identify modulators which modulate function of a polypeptide of Claim 1, which comprises contacting a test compound or sample with the polypeptide, and detecting an activity of the test compound or sample to modulate the function of the polypeptide.
16. A modulator obtainable by a screening method of Claim 15.

17. A pharmaceutical composition for treatment of conditions associated with biological function of a human vanilloid receptor-like protein, which comprises a therapeutically effective amount of a modulator of Claim 16 and a pharmaceutically acceptable carrier.

18. The pharmaceutical composition according to claim 17, wherein said conditions are selected from pain, nociceptive pain, chronic pain, neuropathic pain, postoperative pain, cancer pain, rheumatoid arthritic pain, osteoarthritis, diabetic neuropathies, neuralgia, neuropathies, algesia, nerve injury, muscle-skeletal pain, low back pain, neurodegeneration, stroke, inflammatory disorders, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension and perivascular disease.

19. Use of a modulator according to claim 16 in the manufacture of a medicament for the treatment of a condition associated with biological function of a human vanilloid receptor-like protein.

20. Use according to claim 19, wherein said condition is pain, nociceptive pain, chronic pain, neuropathic pain, postoperative pain, cancer pain, rheumatoid arthritic pain, osteoarthritis, diabetic neuropathies, neuralgia, neuropathies, algesia, nerve injury, muscle-skeletal pain, low back pain, neurodegeneration, stroke, inflammatory disorders, asthma, allergy, urogenital disorders, incontinence, hypertension, hypotension and perivascular disease.

21. A non-human transgenic animal model for vanilloid receptor-like gene function, wherein the transgenic animal has an alteration in vanilloid receptor-like function relative to a normal animal of the same species.






Fig. 1(A): Mock Transfectant




Fig. 1(B): hVRL-2a Transfected/Non-transfected CHO-K1 Cells




Fig. 2(A): Mock Transfectant




Fig. 2(B): hVRL-2a Transfected/Non-transfected HEK293 Cells



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 4663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	WO 99 37675 A (BRAKE ANTHONY J ; JULIUS DAVID J (US); UNIV CALIFORNIA (US); CATERI) 29 July 1999 (1999-07-29) SEQ.ID.N.34 * abstract * * page 2, line 35 - page 3, line 29 * * page 9, line 7 - page 10, line 2 * * page 11, line 9-13 * * page 23, line 26 - page 26, line 20 * * page 29, line 19 - page 37, line 12 * ---	1-21	C07K14/435 C07K14/705 C07K16/28 C12N15/11 C12Q1/68 C12N15/66 A61K38/17 A61P23/00
A,D	CATERINA M J ET AL: "THE CAPSAICIN RECEPTOR: A HEAT-ACTIVATED ION CHANNEL IN THE PAIN PATHWAY" NATURE, MACMILLAN JOURNALS LTD. LONDON, GB, vol. 389, 23 October 1997 (1997-10-23), pages 816-824, XP002075020 ISSN: 0028-0836 * the whole document * ---	1-12	
A	WO 99 00115 A (DAVIS JOHN ; PARSONS ANDREW (GB); BENHAM CHRISTOPHER DAVID (GB); SM) 7 January 1999 (1999-01-07) * the whole document * ---	1,15-20	TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07K A61K
		-/--	
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 27 September 2001	Examiner Mateo Rosell, A.M.
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons ..... & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P/4C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 4663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	ACS G ET AL: "TRIFLUOROPERAZINE MODULATES (3H)RESINIFERATOXIN BINDING BY HUMAN AND RAT VANILLOID (CAPSAICIN) RECEPTORS AND AFFECTS 45CA UPTAKE BY ADULT RAT DORSAL ROOT GANGLION NEURONES" JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 274, no. 3, 1 September 1995 (1995-09-01), pages 1090-1098, XP000864508 ISSN: 0022-3565 * the whole document *	15-17,19	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
A	WALPOLE C S J ET AL: "THE DISCOVERY OF CAPSAZEPINE, THE FIRST COMPETITIVE ANTOAGONIST OF THE SENSORY NEURON EXCITANTS CAPSAICIN AND RESINIFERATOXIN" JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 37, no. 13, 24 June 1994 (1994-06-24), pages 1942-1954, XP000576031 ISSN: 0022-2623 * the whole document *	15-17,19	
A	DRAY A: "NEUROPHARMACOLOGICAL MECHANISMS OF CAPSAICIN AND RELATED SUBSTANCES" BIOCHEMICAL PHARMACOLOGY, PERGAMON, OXFORD, GB, vol. 44, no. 4, 18 August 1992 (1992-08-18), pages 611-615, XP000576776 ISSN: 0006-2952 * the whole document *	15-17,19	
The present search report has been drawn up for all claims			
Place of search <b>BERLIN</b>		Date of completion of the search <b>27 September 2001</b>	Examiner <b>Mateo Rosell, A.M.</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 4663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	LEE J ET AL: "3-Acyloxy-2-phenalkylpropyl Amides and Esters of Homovanillic Acid as Novel Vanilloid Receptor Agonists" BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, vol. 9, no. 20, 18 October 1999 (1999-10-18), pages 2909-2914, XP004180508 ISSN: 0960-894X * the whole document *	15-17,19	
A	PERKINS M N ET AL: "CAPSAZEPINE REVERSAL OF THE ANTINOCICEPTIVE ACTION OF CASAICIN IN VIVO" BRITISH JOURNAL OF PHARMACOLOGY, BASINGSTOKE, HANTS, GB, vol. 107, no. 2, 1 October 1992 (1992-10-01), pages 329-333, XP000576708 ISSN: 0007-1188 * the whole document *	15-17,19	
A	SZALLASI A ET AL: "A NOVEL AGONIST, PHORBOL 12-PHENYLACETATE 13-ACETATE 20-HOMOVANILLATE, ABOLISHES POSITIVE COOPERATIVITY OF BINDING BY THE VANILLOID RECEPTOR" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 299, no. 1 - 3, 1996, pages 221-228, XP002059195 ISSN: 0014-2999 * the whole document *	15-17,19	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search BERLIN		Date of completion of the search 27 September 2001	Examiner Mateo Rosell, A.M.
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 4663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
A	SZALLASI A ET AL: "BINDING OF NEUROLEPTIC DRUG (TRIFLUOPERAZINE AND RIMCAZOLE) TO VANILLOID RECEPTORS IN PORCINE DORSAL HORN" EUROPEAN JOURNAL OF PHARMACOLOGY, AMSTERDAM, NL, vol. 298, no. 3, 18 March 1996 (1996-03-18), pages 321-327, XP001028115 ISSN: 0014-2999 * the whole document *	15-17,19	
P,X	WO 00 32766 A (DELANY NATALIE SAMANTHA ;TATE SIMON NICHOLAS (GB); GLAXO GROUP LTD) 8 June 2000 (2000-06-08) * abstract * SEQ.ID.N.5 * page 2, line 34 - page 7, line 22; figure 19; examples 9-15 *	1-20	
P,X	WO 01 34805 A (ABBOTT LAB) 17 May 2001 (2001-05-17) SEQ.ID.N.1 * page 2, line 10 - page 3, line 30; figure 8; examples 1,2,6,10,12-14 *	1-20	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
P,X	LIEDTKE WOLFGANG ET AL: "Vanilloid receptor-related osmotically activated channel (VR-OAC), a candidate vertebrate osmoreceptor." CELL, vol. 103, no. 3, 27 October 2000 (2000-10-27), pages 525-535, XP002178632 ISSN: 0092-8674 * the whole document *	1-20	
		-/--	
The present search report has been drawn up for all claims			
Place of search <b>BERLIN</b>		Date of completion of the search <b>27 September 2001</b>	Examiner <b>Mateo Rosell, A.M.</b>
CATEGORY OF CITED DOCUMENTS X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document		T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document	

EPO FORM 1503 03.82 (P04C01)



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 01 30 4663

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
P,X	WO 00 50387 A (KIM HEE DOO ;OH UHTAEK (KR); PARK YOUNG HO (KR); SUH YOUNG GER (KR) 31 August 2000 (2000-08-31) * the whole document *	1,15-20	
P,X	WAHL P ET AL: "IODO-RESINIFERATOXIN, A NEW POTENT VANILLOID RECEPTOR ANTAGONIST" MOLECULAR PHARMACOLOGY, BALTIMORE, MD, US, vol. 59, no. 1, January 2001 (2001-01), pages 9-15, XP001028112 ISSN: 0026-895X * the whole document *	15-17,19	
P,X	SZALLASI ARPAD ET AL: "New perspectives on enigmatic vanilloid receptors." TRENDS IN NEUROSCIENCES, vol. 23, no. 10, October 2000 (2000-10), pages 491-497, XP001027974 ISSN: 0166-2236 * the whole document *	1,15-17, 19	
T	DATABASE EMBL [Online] SWALL:AAK69487, 6 September 2001 (2001-09-06) Database accession no. AAK69487; XP002178634 VANILLOID RECEPTOR-LIKE PROTEIN 2.VRL2. Homo sapiens * abstract *	1-12	TECHNICAL FIELDS SEARCHED (Int.Cl.7)
The present search report has been drawn up for all claims			
Place of search <b>BERLIN</b>		Date of completion of the search <b>27 September 2001</b>	Examiner <b>Mateo Rosell, A.M.</b>
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.82 (P04C01)

**ANNEX TO THE EUROPEAN SEARCH REPORT  
ON EUROPEAN PATENT APPLICATION NO.**

EP 01 30 4663

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report.  
The members are as contained in the European Patent Office EDP file on  
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

27-09-2001

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9937675	A	29-07-1999	AU	2466799 A	09-08-1999
			AU	9115698 A	08-03-1999
			EP	1009804 A1	21-06-2000
			EP	1047711 A1	02-11-2000
			WO	9909140 A1	25-02-1999
			WO	9937675 A1	29-07-1999
-----					
WO 9900115	A	07-01-1999	WO	9900115 A1	07-01-1999
			EP	1003491 A1	31-05-2000
-----					
WO 0032766	A	08-06-2000	AU	1968400 A	19-06-2000
			WO	0032766 A1	08-06-2000
			EP	1135490 A1	26-09-2001
-----					
WO 0134805	A	17-05-2001	WO	0134805 A2	17-05-2001
-----					
WO 0050387	A	31-08-2000	AU	2697600 A	14-09-2000
			WO	0050387 A1	31-08-2000
-----					